PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 1
A PHASE 1/2, RANDOMIZED, OBSERVER -BLINDED TRIAL TO EVA LUATE 
THE SAFETY, TOLERABILITY, AND IMMUNOGENI CITY OF A MULTIVALENT 
PNEUMOCOCCAL CONJUGA TE VACCINE IN HEALTH Y ADULTS 50 
THROUGH 85 YEARS OF AGE
Investigational Product Number: PF
-06842433
Investigational Product Name: Complementary 7-valen t Pneumococcal 
Conjugate V accine
United States (US) Investigational N ew 
Drug (IND) Number:To B e Determined (TBD)
European Clinical Trial sDatabase 
(EudraCT) Number:Not Applicable ( N/A)
Protocol Number: C357100 1
Phase: 1/2

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 2Document History
Document Version Date Summar y of Changes
Original protocol 28June 2017 N/A

PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 3TABLE OF CONTENTS
LIST OF TABLES................................................................................................................. ....7
APPENDICES ..................................................................................................................... ......7
PROTOCOL SUMMARY.........................................................................................................8SCHEDULE OF AC TIVITIES................................................................................................12
1. INTRODUCTION ...............................................................................................................1 6
1.1. Indica tion................................................................................................................ .16
1.2. Background and Rationale ......................................................................................16
1.2.1. Disease and Disease Burden.......................................................................161.2.2. Vaccines to Prevent Pneumococcal Disease...............................................16
1.2.2.1. Pneumococcal Polysaccharide Vaccines...................................161.2.2.2. Pneumococcal Polysaccharide Conjugate Vaccines .................171.2.2.3. Rationale for c7vPnC ................................................................18
2. STUDY OBJECTIVES AND ENDPOINTS.......................................................................18
2.1. Primary Objectives and Endpoints..........................................................................18
2.1.1. Primary Objectives .....................................................................................182.1.2. Primary Endpoints ......................................................................................19
2.2. Secondary Objectives and Endpoints......................................................................19
2.2.1. Secondary Objectives .................................................................................192.2.2. Secondary Endpoints ..................................................................................19
3. STUDY DESIGN................................................................................................................ .20
3.1. Duration of Subject Participation............................................................................213.2. Duration of the Study ..............................................................................................213.3. Number of Subjects.................................................................................................22
4. SUBJECT ELIGIBILITY CRITERIA.................................................................................22
4.1. Inclusion Criteria.....................................................................................................22
4.2. Exclusion Criteria....................................................................................................244.3. Temporary D elay Cr iteria .......................................................................................26CCI
PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 44.3.1. Criteria for Temporaril y Dela ying Vaccine Administration (Stage 1 
and S tage 2: Visit 1) .........................................................................................27
4.3.2. Criteria for Temporaril y Dela ying Immunogenicity  Blood Draw 
(Stage 1: Visit 1 and Visit 2; Stage 2: Visits 1, 2, and 4) ................................27
4.4. L ifesty le Requirements ...........................................................................................27
4.4.1. Contraception ................................
..............................................................27
4.5. Sponsor’s Qualified Medical Personnel ..................................................................28
5. INVESTIGAT IONAL P RODUCTS ...................................................................................29
5.1. Allocation to I nvestigational Product ......................................................................29
5.2. Blinding of the Site Personnel .................................................................................29
5.3. Blinding of the Sponsor...........................................................................................30
5.4. Breaking the Blind
................................................................
..................................30
5.5. Subject Compliance .................................................................................................30
5.6. I nvestigational Product Supplies .............................................................................30
5.6.1. Dosage Form (s) and Packaging ..................................................................31
5.6.2. Preparation and Dispensing ........................................................................31
5.7. Administration .........................................................................................................31
5.8. I nvestigational Product Storage ..............................................................................32
5.9. I nvestigational Product Accountabilit y...................................................................33
5.9.1. Destruction of In
vestigational Product Supplies ........................................33
5.10. Prior Vaccination (Stage 2 Only ) ..........................................................................33
5.11. Concomitant Treatment(s) ................................
.....................................................33
5.11.1. Prohibited Concomitant Treatments.........................................................33
5.11.2. Permitted Concomitant Treatments (Stage 1 and Stage 2 Subjects) ........34
5.11.3. Recording Concomitant Treatments.........................................................34
6. STUDY PROCEDURES ................................ ................................ ................................ .....34
6.1. Stage 1 Study  Proc edures ........................................................................................34
6.1.1. Screening (14 to 2 Day s Prior to Vaccination) – Clinic Visit ....................34
6.1.2. Visit 1 (Day  1; Day  of Vaccination) –Clinic Visit ....................................35
6.1.3. Visit 2 (Month 1; 28 to 35 Day s After Vaccination) –Clinic Visit ...........37
6.1.4. Visit 3 (Month 6; 168 to 196 Da ys After Vaccination) – Telephone 
Contact ................................ ................................ ................................ ............. 37
6.2. Stage 2 Study  Procedures ........................................................................................38

PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 56.2.1. Visit 1 (Day 1; Day of Vaccination) – Clinic Visit ....................................38
6.2.2. Visit 2 (Month 1; 28 to 35 Days After Vaccination) – Clinic Visit ...........396.2.3. Visit 3 (Month 6; 168 to 196 Days After Vaccination) – Telephone 
Contact .............................................................................................................40
6.2.4. Visit 4 (Month 12; 350 to 378 Days After Vaccination) – Clinic Visit .....40
6.3. Unscheduled Visits (Stage 1 and Stage 2) ..............................................................416.4. Subject Withdrawal .................................................................................................42
6.4.1. Withdrawal of Consent...............................................................................426.4.2. Lost to Follow-up .......................................................................................42
7. ASSESSMENTS................................................................................................................. .43
7.1. Pregnanc y Testing ...................................................................................................43
7.2. Safety Parameter s....................................................................................................44
7.2.2. Subject Electronic Diary.............................................................................46
7.2.3. Grading Scale for Prompted Events ...........................................................46
7.2.3.1. Local Reactions .........................................................................467.2.3.2. Systemic Events ........................................................................477.2.3.3. Fever..........................................................................................487.2.3.4. Use of Antipyretic/Pain Medication..........................................49
7.3. Immunogenicity ......................................................................................................497.4. Laboratory Tests:  Stage 1 Only..............................................................................49
7.5. Biological Samples..................................................................................................50
8. ADVERSE EVENT REPORTING......................................................................................50
8.1. Requirements...........................................................................................................50
8.1.1. Additional Details on Recording Adverse Events on the CRF...................518.1.2. Eliciting Adverse Event Information..........................................................528.1.3. Withdrawal From the Study Due to Adverse Events (see also the 
Subject Withdrawal Section) ...........................................................................52
8.1.4. Time Period for Collecting AE/SAE Information......................................52
8.1.4.1. Reporting SAEs to Pfizer Safety...............................................528.1.4.2. Recording Nonserious AEs and SAEs on the CRF...................52
8.1.5. Causality Assessment .................................................................................53
8.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities ..................53CCI
PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 68.2. Definitions............................................................................................................... 53
8.2.1. Adverse Events ...........................................................................................538.2.2. Abnormal Test Findings .............................................................................548.2.3. Serious Adverse Events ..............................................................................548.2.4. Hospitalization............................................................................................55
8.3. Severity Assessment................................................................................................578.4. Special Situations ....................................................................................................57
8.4.1. Protocol-Specified Serious Adverse Events ...............................................578.4.2. Potential Cases of Drug-Induced Liver Injury............................................578.4.3. Exposure to the Investigational Product During Pregnancy or 
Breastfeeding, and Occupational Exposure .....................................................59
8.4.3.1. Exposure During Pregnancy......................................................598.4.3.2. Exposure During Breastfeeding ................................................608.4.3.3. Occupational Exposure .............................................................60
8.4.4. Medication Errors .......................................................................................61
8.5. Medical Device Complaint Reporting Requirements .............................................62
9. DATA ANALYSIS/STAT ISTICAL METHODS...............................................................62
9.1. Sample Size Determination.....................................................................................629.2. Analysis Populations ...............................................................................................639.3. Immunogenicity Analysis .......................................................................................649.4. Safety Analysis........................................................................................................64
9.5. Analysis Timing ......................................................................................................65
10. QUALITY CONTROL AND QUALITY ASSURANCE.................................................66
11. DATA HANDLING AND RECORD KEEPING .............................................................66
11.1. Case Report Forms/Electronic Data Record .........................................................6611.2. Record Retention...................................................................................................67
12. ETHICS..................................................................................................................... .........67
12.1. Institutional Review Board/Ethics Committee......................................................6712.2. Ethical Conduct of the Study ................................................................................6812.3. Subject Information and Consent..........................................................................68
12.4. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH 
GCP ...........................................................................................................................6 8
CCI
PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 713. DEFI NITION OF EN D OF TRIAL ...................................................................................69
13.1. End of Trial in the Participating Country ..............................................................69
14. SPONSOR DI SCONTI NUATION CRITERIA ................................................................69
15. PUBLICATION OF S TUDY RESUL TS..........................................................................69
15.1. Communication of Results by  Pfizer ................................ ................................ ....69
15.2. Publications by  Investigators ................................................................................70
16. REFERENCES ..................................................................................................................72
LIST OF TABLES
Table 1. Grading Scales for Local Reactions .....................................................................47
Table 2. Grading Scales for Sy stemic Events .....................................................................48
Table 3. Ranges for Fever ...................................................................................................48
Table 4. Probability  of Observing at Least 1 AE, Local Reaction, or Sy stemic Event 
by Assumed True Event Rat es With Different Sample Sizes ............................... 62
APPENDICES
Appendix 1. Abbreviations ......................................................................................................79

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 8PROTOCOL SUMMARY
Background and Rationale
Streptococcus pneumoniae are gram -positive encapsulated cocci that have been a leading 
cause of meningitis, bacteremia, pneumonia, and acute otitis media (AOM) and continue to 
be a major global pub lic health concern. Serious pneumococcal disease may  occur at any  
age;however, children <5 y ears and adults  65 years of age are at particularly  increased risk.  
Individuals with certain comorbidities and immunocompromising conditions are also at risk. 
Data from t he Centers for Disease Control and Prevention (CDC )estimated that in 201 5
there were 29,500 cases and 3350 deaths due to invasive pneumococcal disease (IPD)in 
persons of all ages in the United States. Spneumoniae remains an important cause o f serious 
disease in the U nited States and worldwide .
The Spneumoniae pol ysaccharide capsule has been identified as an important virulence 
factor for this pathogen. While there are more than 95 pneumococcal seroty pesdifferentiated 
by their capsular pol ysaccharide composition, a subset ismore commonly  associated with 
severe disease.   Pneumococcal disease can be prevented with poly saccharide -based vaccines 
that induce antibod y responses with functional (opsonophagocytic) activity and target the 
capsular s erotypes responsible for disease.  Thelicensed 23 -valent pneumococcal 
polysaccharide vaccine (PPSV23), however, has
substantial disadvantages because it 
contains poly saccharides in an unconjugated manner with its inherent limitations in terms of 
quantity  and quality  of immune responses. T he incidence of IPD due to the serot ypes unique 
to PPSV23 has remained relativel ystable or slightly  increased over the past 15 y ears, despite 
continued recommendation and use of PPSV23 in adults  65years of age and high
-risk 
adults. Therefore, unconjugated poly saccharide vaccines have significant limitations.
Pneumococcal conjugate vaccines ,which contain poly saccharide antigens covalentl y linked 
to a protein carrier ,elicit a T -cell–dependent immune response inducing p rotective responses 
in young children, older adults, and populations with high -risk conditions.
Prevnar,licensed in the U nited States in 2000, and Prevnar 13 ,licensed in the United 
States in 2010, are pneumococcal conjugate vaccines containing 7 and 13 pneumococcal 
polysaccharide conjugates ,respectivel y.  These vaccines have demonstrated 
efficacy /effectiveness against vaccine
-type (VT) IPD, AOM, and pneumonia in infants and 
older adults.  They  also have demonstrated the ability  to reduce nasophary ngeal carriage and 
transmission, resulting i n indirect beneficial effects.
However, there continues to be pneumococcal disease due to other serot ypesnot included in 
either Prevnar or Prevnar 13 in various age groups and in different parts of the world. Seven 
seroty pes, 8, 10A, 11A, 12F, 15B, 22F, and 33F ,continue to be a cause of pneumococcal 
disease in both children and adults, across different geographic regions. These 7serot ypes 
are contained in PPSV23, a licensed vaccine in use for over 30 years, indica ting that despite 
the evolving pneumococcal epidemiolog y and use of PPSV23, the significant disease burden 
caused b y these serot ypes has not been adequatel y addressed .

PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 9Pfizer is developing a new complementary 7-valent pneumococcal conjugate vaccine 
(c7vPnC) candidate to augment current pneumococcal coverage in children and adults. c7vPnC contains pneumococcal conjugates of 7 different serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) to protect against pneumococcal disease caused by these serotypes.  c7vPnC contains the same conjugate carrier protein and excipients and uses the same platform as Prevnar and Prevnar 13.
The purpose of this Phase 1/2 study is to provide safety, tolerability, and immunogenicity 
data for c7vPnC in adults 50 through 85 years of age and will support further clinical development.
Study Design
This is a 2-stage, Phase 1/2, randomized, active-controlled, observer-blinded study with a 
2-arm parallel design. It is planned to be conducted at investigator sites in the United States.  The purpose of Stage 1 is to provide first-in-human (FIH) safety and immunogenicity data with the investigational pneumococcal vaccine c7vPnC in adults 50 to 64 years of age, and it serves as the Phase 1 part of the study.  Stage 2 functions as the Phase 2 part of the study and will provide additional safety and immunogenicity data with c7vPnC in adults 65 to 85 years of age, compared to PPSV23.
Stage 1:
In Stage 1 of the study, approximately 66 adults 50 through 64 years of age with no history 
of pneumococcal vaccination will be randomized equally to receive a dose of c7vPnC or licensed tetanus, diphtheria, and acellular pertussis vaccine (Tdap) as the control vaccine.  
  
  Subjects will have blood drawn for safety 
laboratory testing and immunogenicity assessments at protocol-specified time points.  Prompted local reactions and systemic events occurring within 14 days after vaccination will be collected each day in an electronic diary (e-diary). Safety will be assessed through 6 months after vaccination.
 
 
Stage 2:
In Stage 2 of the study, approximately 440 adults 65 through 85 years of age previously 
vaccinated with Prevnar 13 ≥2 months prior to investigational product administration, as part 
of their routine medical care, will be randomized equally to receive a dose of c7vPnC or CCICCI
PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 10PPSV23 as the control vaccine.  Blood will be collected for immunogenicity assessments at
protocol-specified time points.  Prompted local reactions and systemic events occurring within 14 days of vaccination will be collected each  day in the e-diary.  Safety will be 
assessed through 12 months after vaccination.
 
 
 
Primary Objectives and Endpoints
Primary Objectives
•Stage 1: To describe the safety profile of c7vPnC in adults 50 through 64 years of age.
•Stage 2: To describe the safety profile of c7vPnC in adults 65 through 85 years of age.
Primary Endpoints
•Proportions of subjects reporting prompted local reactions within 14 days after 
vaccination (redness, swelling, and pain at the injection site).
•Proportions of subjects reporting prompted systemic events within 14 days after 
vaccination (fever, headache, fatigue, muscle pain, and joint pain).
•Proportions of subjects reporting AEs within 1 month after vaccination.
•Proportions of subjects reporting serious adverse events (SAEs) and newly diagnosed 
chronic medical conditions (NDCMCs) within 6 months after vaccination (both Stage 1 
and Stage 2) and within 12 months after vaccination (Stage 2 only).
Secondary Objectives and Endpoints
Secondary Objectives
•Stage 1: To describe the immunogenicity of c7vPnC in adults 50 through 64 years of age.
•Stage 2: To describe the immunogenicity of c7vPnC in adults 65 through 85 years of age.
Secondary Endpoints
•Pneumococcal serotype-specific opsonophagocytic activity (OPA) geometric mean titers 
(GMTs) at 1 month after vaccination.CCI
PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 11•Pneumococcal serotype-specific OPA geometric mean fold rises (GMFRs) from before 
vaccination to 1 month after vaccination.
Statistical Methods
All safety and immunogenicity analyses will be descriptive and will be summarized by group 
with point estimates and 95% confidence intervals.CCI
PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 12SCHEDULE OF ACTIVITIES
The schedule of activities table provides an overview of the protocol visits and procedures.  Refer to the Study Procedures and  
Assessments sections of the protocol for detailed information on each procedure and assessment required for compliance with the  
protocol.
The investigator may schedule visits (unplanned visits) in addition to those listed on the schedule of activities table, in order  to 
conduct evaluations or assessments required to protect the well-being of the subject.
Stage 1:
Visit Identifier Screening 1 2 3
Visit Description Screening Day 1 Month 1 Month 6
Visit Type Clinic Visit Clinic Visit Clinic Visit Telephone Contact
Visit Window 14 to 2 Days Before Day 
1Day of Vaccination 28 to 35 Days
After Vaccination168 to 196 Days After 
Vaccination
Obtain informed consent X
Assign subject number X
Record demography X
Obtain medical history X
Perform physical examination X
Measure prevaccination oral temperature X
Perform urine pregnancy test for female subjects of childbearing 
potentialX
Contraception check, if applicableaXX X
Record nonstudy vaccinations and concomitant medications X X X X
Review inclusion and exclusion criteria X X
Review temporary delay criteria XX
Review continued eligibility X
Obtain blood sample for safety laboratory assessments (~10 mL) X
Assign randomization number X
Obtain blood sample for immunogenicity (~50 mL) XbX
Administer investigational product (c7vPnC or Tdap) X
Assess and record acute reactions for at least 30 minutes after 
investigational product administrationXC
CI
PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 13Visit Identifier Screening 1 2 3
Visit Description Screening Day 1 Month 1 Month 6
Visit Type Clinic Visit Clinic Visit Clinic Visit Telephone Contact
Visit Window 14 to 2 Days Before Day 
1Day of Vaccination 28 to 35 Days
After Vaccination168 to 196 Days After 
Vaccination
Provide subject with e -diary, thermometer ,and measuring device ,
provide instructions on use, and instruct subject to collect prompted 
local reactions and systemic events daily until Day 14cX
Review e -diary eventsd,eX X
Collect e -diary X
Record and report AEsf,gX-------------------------------------------------------X
Record and report SAEs and NDCMCshX------------------------------ X
Abbreviations: e -diary = electronic diary; NDC MC= newly diagnosed chronic medical c ondition .
a. The investigator or designee will inform the subject of the need to use highly effective contraception consistently and correc tly until 28 days after vaccine administration and 
document the conversation and the subject’s affirmation in the subject’s chart .
b. Blood sample will be collected prior to vaccination.
c. Subjects will record prompted local reactions ,systemic events , fever, and antipyretic/pain medication used to treat symptoms in an e -diary each evening for 14 days following 
vaccination.  Subjects will be asked to contact the study staff if they experience a Grade 3 or possible Grade 4 reaction at the injection site , fever >104.0 F (>40.0C), or any 
possible Grade 4 prompted systemic event.
d. Designated site staff will review e -
diary data online at frequent intervals (daily is optimal) for the 14 days following vaccination to evaluate subject compliance and as part of 
the ongoing safety review.
e. If a stopping rule is confirmed, the subject(s) will be asked to return to the site as soon as possible for further evaluation of reported events.
f. Subjects will be asked to contact the study staff if they experience a severe nonprompted AE or any SAE during the 14 -day postvaccination period.
g. Adverse events include nons erious AEs, SAEs, and NDCMCs.
h. An NDCMC is defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long -lasting in its effects.

PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 14Stage 2:
Visit Identifier 1 2 3 4
Visit Description Day 1 Month 1 Month 6 Month 12
Visit Type Clinic Visit Clinic Visit Telephone Contact Clinic Visit
Visit Window Day of Vaccination 28 to 35 Days
After Vaccination168 to 196 Days
After Vaccination350 to 378 Days
After Vaccination
Obtain informed consent X
Assign subject number X
Record demography X
Obtain medical history X
Record prior Prevnar 13 vaccination X
Perform physical examination X
Measure prevaccination oral temperature X
Contraception check, if applicableaXX
Record nonstudy vaccinations and concomitant medications X X X X
Review inclusion and exclusion criteria X
Review temporary delay criteria X X X
Review continued eligibility XX
Assign randomization number X
Obtain blood sample for immunogenicity (~50 mL) XbX
Administer investigational product (c7vPnC or PPSV23) X
Assess and record acute reactions for at least 30 minutes after 
investigational product administrationX
Provide subject with e-diary, thermometer, and measuring device,
provide instructions on use, and instruct subject to collect prompted local reactions and systemic events daily until Day 14
cX
Review e-diary eventsdXXC
CI
PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 15Visit Identifier 1 2 3 4
Visit Description Day 1 Month 1 Month 6 Month 12
Visit Type Clinic Visit Clinic Visit Telephone Contact Clinic Visit
Visit Window Day of Vaccination 28 to 35 Days
After Vaccination168 to 196 Days
After Vaccination350to 37 8Days
After Vaccination
Collect e -diary X
Record and report AEse,fX--------------------------- X
Record and report SAEs and NDCMCsgX--------------------------------------------------------------X
Abbreviations: e -diary = electronic diary; NDCMC = newly diagn osed chronic medical condition.
a. The investigator or designee will inform the subject of the need to use highly effective contraception consistently and corre ctly until 28 days after vaccine administration and 
document the conversation and the subject’s af firmation in the subject’s chart.
b. Blood sample will be collected prior to vaccination.
c. Subjects will record prompted local reactions ,systemic events , fever, and antipyretic/pain medication used to treat symptoms in an e -diary each evening for 14 days following 
vaccination.  Subjects will be asked to contact the study staff if they experience a Grade 3 or possible Grade 4 reaction at the injection site, fever >104.0 F (>40.0C), or any 
possible Grade 4 prompted systemic event.
d. Designated site staff will rev iew e -diary data online at frequent intervals (daily is optimal) for the 14 days following vaccination to evaluate subject complian ce and as part of 
the ongoing safety review.
e. Subjects will be asked to contact the study staff if they experience a severe nonprompted AE during the 14 -
day postvaccination period.
f. Adverse events include nonserious AEs, SAEs, and NDCMCs.
g. An NDCMC is defined as a disease or medical condition, not previously identified
,that is expected to be persistent or otherwise long -lasting in its effects.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 161. INTRODUCTION
1.1.Indication
Complementary 7-valent pneumococcal conjugate vaccine (c7vPnC) is being developed for:
Active immunization to prevent invasive disease and pneumonia caused by  the 
Streptococcus pneumonia eserot ypes in the vaccine.
1.2. B ackground and Rationale
1.2.1. Disease and Disease Burden
S pneumoniae are gram -positive encapsulated cocci that have been a leading cause of 
meningitis, bacteremia, pneumonia, and acute otitis media (AOM) and continue to be a major 
global public health concern.1,2,3Serious pneumococcal disease may  occur at any  age;
however, children <5 years and adults  65 years of age are at particularl y increased risk.4  
Individuals with certain comorbidities and immunocompromising conditions are also at risk.  
S pneumoniae remains among the most common pathogens identified in community -acquired 
pneumonia (CAP) requiring hospitalization in the U nited States in both children and adults .5,6  
Although invasive pneumococcal disease (I PD) is less common than pneumococcal 
pneumonia, particularly  with the introduction of the efficacious pneumococcal conjugate 
vaccines described below, there remains a burden of disease in all age groups and associated 
morbidity  and mortality .7  Data from the Centers for Disease Control and Prevention (C DC) 
estimated that in 2015 there were 29,5
00 cases and 3350 deaths due to IPD in persons of all 
ages in the U nited States.8In man y regions of the world the disease burden is much higher, 
reflected in an assessment by  the World Health Organization (WHO) i n 2008 estimating that 
1.6 million people die from pneumococcal disease each year.9  Thesedata show that 
Spneumoniae remains an important cause of serious disease in the U nited States and 
worldwide.
The S pneumoniae polysaccharide capsule has been identi fied as an important virulence 
factor for this pathogen. While there are more than 95 pneumococcal seroty pes differentiated 
by their capsular pol ysaccharide composition, a subset is more commonly  associated with 
severe disease.10,11Pneumococcal disease ca n be prevented with poly saccharide -based 
vaccines that induce antibody responses with functional (opsonophagocy tic) activity
 and 
target the capsular serotypes responsible for disease.
1.2.2. Vaccines to Prevent Pneumococcal Disease
1.2.2.1. Pneumococcal Polysaccharide Vac cines
Vaccines containing unconjugated polysaccharides have been licensed since the 1970s.  One 
such vaccine, the 23 -valent pneumococcal polysaccharide vaccine (PPSV23) ,has been 
licensed in the U nited States since 1983.12,13PPSV23 contains unconjugated capsular 
polysaccharides for 23 seroty pes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 
17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).  PPSV23 elicits a T -cell–independent immune 
response.  PPSV23 induces only  limited responses to many  important pneumococcal 
seroty pes in children less than 2 y ears of age and does not induce a memory  response in any  

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 17population.4,14,15  Inaddition, in several studies, individuals vaccinated with pneumococcal 
polysaccharide vaccine had lower functional antibody  responses following subsequent 
vaccination with either another dose of pneumococcal pol ysaccharide vaccine ora dose of
conjugate vaccine, compared to the first dose of poly saccharide vaccine, resulting in 
hyporesponsi veness .16,17
,18  Furthermore , several studies have failed to demonstrate the 
effectiveness of PPSV23 in preventing nonbacteremic CAP pneumonia in older 
individuals.4,19,20  Several studies have shown that its effectiveness against IPD declines 
within 5 y ears.4,13,15  Therefore, unconjugated polysaccharide vaccines have significant 
limitations.
1.2.2.2. Pneumococcal Polysaccharide Conjugate Vaccines
Pneumococcal conjugate vaccines contain poly saccharides that are covalently  linked 
(conjugated) to an immunogenic protein.  This modification results in T -cell
–dependent 
immune responses ,
which have been shown to be protective in y oung children, older adults, 
and populations with high -risk conditions.14,21  Prevnar(7-valent pneumococcal conjugate 
vaccine [7vPnC ]) was the first pneumococcal conjugate vaccine to be licensed (2000) and 
was indicated for the prevention of pneumococcal disease in infants and y oung children on 
the basis of efficacy  studies.  Prevnar contained capsular poly saccharide conjugates for 
7pneumococcal serot ypes ( 4, 6B, 9V, 14, 18C, 19F, and 23F) ,each covalently  linked to the 
cross -reactive material 197 (CRM 197), a nontoxic variant of diphtheria toxin. Prevnar 
demonstrated efficacy  against vaccine -type (VT) IPD, pneumonia, and AOM in large 
randomized controlled efficacy /effectiveness studies in infants.22,23,24  
ThePrevnar 
components contained in a related pneumococcal conjugate vaccine also were demonstrated 
to be efficacious against clinically /radiographically  defined pneumonia.25,26,27
,28  Following 
introduction of Prevnar , reduction of nasophary ngeal carriage and tr ansmission has resulted 
in indirect herd effects, with a 92% reduction of 7vPnC VT I PDin older adults  65 years of 
age.29,30
At the time of introduction, Prevnar covered the majority
 of serot ypes responsible for I PD in 
US infants ;however, additional seroty pes not included in Prevnar accounted for a significant 
proportion of AOM in that population, as well as IPD in older adults in the United States and 
children outside of the U nited States.  Therefore, Prevnar 13 was developed to expand 
seroty pe coverage a nd was licensed in the U nited States in 2010.  Prevnar 13 includes the 
same S pneumoniae seroty pes as Prevnar and an additional 6 poly saccharide conjugates for 
seroty pes (1, 3, 5, 6A, 7F, and 19A).21,31  The addition of the 6 s erotypes expanded the 
percentage of vaccine -preventable IPD cases to 90% in most regions of the world.21,31
Prevnar 13 has replaced Prevnar and is licensed in the United States an d many  other 
countries, with national recommendations for use in children and older adults.32,33
,34,35It has 
also been prequalified b y WHO for use in national infant immunization programs in lower -
and middle -income countries.36,37  Surveillance data from several countries following 
introduction of Prevnar 13 into the routine infant immunization program have demonstrated 
vaccine effectiveness against VT I PD in the vaccinated population as well as decreases in 
colonization in both children and adults .38
,39,40,41

PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 181.2.2.3. Rationale for c7vPnC
The purpose of this study is to assess the safety and tolerability of c7vPnC in healthy adults 
50 through 85 years of age.  This study represents the initial evaluation of c7vPnC in humans.  In addition to safety, immunogenicity of c7vPnC will also be described. In Stage 1, the inclusion of a control group receiving tetanus, diphtheria, and acellular pertussis vaccine (Tdap) will serve as a benchmark for the rates of local reactions that may be observed with a vaccine that contains CRM
197and has been evaluated and is licensed and recommended for 
use in this age group. In Stage 2, the inclusion of a control group receiving PPSV23 will serve as a benchmark for safety and the rates of local reactions that may be observed with a licensed and recommended pneumococcal vaccine containing the serotypes that are in common with c7vPnC.
Additional information for c7vPnC may be found in the single reference safety document 
(SRSD), which for this study is the c7vPnC IB .  The SRSDs for the Tdap and PPSV23 
control vaccines are the US package inserts (USPIs).
2. STUDY OBJECTIVES AND ENDPOINTS
2.1. Primary Objectives and Endpoints2.1.1. Primary Objectives
•Stage 1:
To describe the safety profile of c7vPnC in adults 50 through 64 years of age.
•Stage 2: To describe the safety profile of c7vPnC in adults 65 through 85 years of age.CCI
PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 192.1.2. Primary Endpoints
•Proportions of subjects reporting prompted local reactions within 14 days after 
vaccination (redness, swelling, and pain at the injection site).
•Proportions of subjects reporting prompted systemic events within 14 days after 
vaccination (fever, headache, fatigue, muscle pain, and joint pain).
•Proportions of subjects reporting adverse events (AEs) within 1 month after vaccination.
•Proportions of subjects reporting serious adverse events (SAEs) and newly diagnosed 
chronic medical conditions (NDCMCs) within 6 months after vaccination (both Stage 1 
and Stage 2) and within 12 months after vaccination (Stage 2 only).
2.2. Secondary Objectives and Endpoints
2.2.1. Secondary Objectives
•Stage 1: To describe the immunogenicity of c7vPnC in adults 50 through 64 years of age.
•Stage 2: To describe the immunogenicity of c7vPnC in adults 65 through 85 years of age.
2.2.2. Secondary Endpoints
•Pneumococcal serotype-specific opsonophagocytic activity (OPA) geometric mean titers 
(GMTs) at 1 month after vaccination.
•Pneumococcal serotype-specific OPA geometric mean fold rises (GMFRs) from before 
vaccination to 1 month after vaccination.
CCI
PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 203. STUDY DESIGN
This is a 2-stage, Phase 1/2, randomized, active-controlled, observer-blinded study with a 
2-arm parallel design. It is planned to be conducted at investigator sites in the United States.The purpose of Stage 1 is to provide first-in-human (FIH) safety and immunogenicity data with the investigational pneumococcal vaccine c7vPnC in healthy adults 50 to 64 years of age, and it serves as the Phase 1 part of the study.  Stage 2 functions as the Phase 2 part of the study and will provide additional safety and immunogenicity data with c7vPnC in healthy adults 65 to 85 years of age, compared to PPSV23.
Stage 1:
In Stage 1 of the study, approximately 66 h ealthy adults 50 through 64 ye ars of age with no 
history of pneumococcal vaccination will be enrolled, screened, and randomized equally in a 1:1 ratio to receive a dose of c7vPnC or Tdap as the control vaccine.  The rate of vaccination 
in Stage 1 will be limited to ≤5 subjects per day until all subjects have been enrolled in this 
stage of the study.  Subjects will be enrolled and have blood drawn for baseline safety laboratory testing (hematology and tests for liver and renal function) at the screening visit (14 to 2 days prior to vaccination).  On Day 1 (Visit 1), subjects will have blood drawn for immunogenicity assessments, receive investigational product, be observed for 30 minutes after vaccination, and receive safety follow-up and electronic diary (e-diary) instructions.  Prompted local reactions (redness, swelling, and pain at the injection site) and systemic events (fever, headache, fatigue, muscle pain, and joint pain) occurring within 14 days aftervaccination will be collected each day in the e-diary.  Approximately 1 month after vaccination (Visit 2), subjects will return to the study site for safety follow-up (ie, collection of AEs [including nonserious AEs, SAEs, and NDCMCs]) and a blood draw (safety laboratory testing [hematology and tests for liver and renal function] and immunogenicity).  A telephone contact will occur 6 months after vaccination (Visit 3) to collect any SAEs or NDCMCs that occurred since the 1-month follow-up visit.
 
   CCI
CCICCI
PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 21 
  
 
Stage 2:
In Stage 2 of the study, approximately 440 healthy adults 65 through 85 years of age
previously vaccinated with Prevnar 13 ≥2 months prior to investigational product
administration, as part of their routine medical care, will be enrolled and randomized equally
in a 1:1 ratio to receive a dose of c7vPnC or PPSV23 as the control vaccine.  On Day 1 (Visit 1), subjects will have blood drawn for immunogenicity assessments, receive investigational product, be observed for 30 minutes after vaccination, and receive safety follow-up and e-diary instructions.  Prompted local reactions and systemic events occurring within 14 days of vaccination will be collected each  day in the e-diary.  Subjects will return 
to the investigator site for safety follow-up (AEs [including nonserious AEs, SAEs, and NDCMCs]) and a blood draw for immunogenicity approximately 1 month after vaccination (Visit 2).  A telephone contact will occur 6 months after vaccination (Visit 3) to collect any SAEs or NDCMCs that occurred since the 1-month follow-up visit.  Subjects will return approximately 12 months after vaccination (Visit 4)  
and any SAEs or NDCMCs occurring in the interim since the 6-month 
telephone contact will be recorded.
 
 
 safety and immunogenicity data 
reviews/analyses will be performed at various time points as described in Section 9 .
3.1. Duration of Subject Participation
Stage 1:
Each subject will participate in the study for approximately 7 months.
Stage 2: Each subject will participate in the study for approximately 12 months.
3.2. Duration of the Study
The study duration (first subject enrolled in Stage 1 until last subject completing Stage 2)
will be approximately 20 months.CCI
CCI
CCICCI
PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 223.3. Number of Subjects
Stage 1: Assuming a 10% dropout rate, approximately  66 subjects will be randomized to 
ensure approximatel y 60 evaluable subjects, with approximate ly 30 subjects in each of 2
group s.
Stage 2: Assuming a 10% dropout rate, a pproximately  440 subjects will be randomized to 
ensure approximatel y 400evaluable subjects, with approximatel y 200 subjects in each of 2
groups.
Subjects who withdraw or are withdr awn from the study  after randomization will not be 
replaced, regardless of the reason for wit hdrawal.
4.SUBJECT 
ELIGIBILITY CRITERIA
This study  can fulfill its objectives only  if appropriate subjects are enrolled.  The following 
eligibility  criteria are desi gned to select subjects for whom participation in the study is 
considered appropriate.  All relevant medical and nonmedical conditions should be taken into 
consideration when deciding whether a particular subject is suitable for this protocol.
Subject eligibility  should be reviewed and documented by  an appropriate member of the 
investigator’s study team before subjects are included in the study .
4.1. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the 
study :
Stage 1
1.Evidence of a personally  signed and dated informed consent document indicating that the 
subject has been informed of all pertinent aspects of the study .
2. Willing and able to comply  with scheduled visits, treatment plan, laboratory tests ,and 
other study  procedures ,including completion of the e -diary .
3.Expected to be available for the duration of the study  and able to be contacted by  
telephone during stud y participation.
4.Male or female adults 50 to <65years of age (from the 50th birthday  up to but not 
including the 65th birthday )at enrollment.
5.Health y adults, including adults with preexisting stable disease, defined as disease not 
requiring significant change in therap y in the last 12 weeks ornot worsening or requiring 
hospitalization withi n 6 months before investigational product administration
, as 
determined b y medical history, ph ysical examination, laboratory  screening, and clinical 
judgment of the investigator.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 236.Male subjects able to father children and female subjects of childbearing potential must 
agree to use a highly effective method of contraception as outlined in the protocol from 
the time of informed consent through at least 28 day s after the last dose of investigational 
product.
7.Negative urine pregnancy  test at Day  1(prior to v accination) for all female subjects who 
are of childbearing potential.
8.Female subjects of nonchildbearing potential must meet at least 1of the following 
criteria:
a.Achieved postmenopausal status, defined as follows: cessation of regular menses for 
at least 12consecutive months with no alternative pathological or phy siological 
cause; status may  be confirmed by having a serum follicle -stimulating hormone 
(FSH) level confirming the postmenopausal state;
b.Have undergone a documented hy sterectomy and/or bilatera l oophorectomy ;
c.Have medic ally confirmed ovarian failure.
All other female subjects (including female subject s with tubal ligations) are considered 
to be of childbearing potential.
Stage 2
1.Evidence of a personally  signed and dated informed consent document indicating that the 
subject has been informed of all pertinent aspects of the study .
2.Willing and able to comply  with scheduled visits, treatment plan, laboratory tests, and 
other study  procedures ,including completion of the e -diary .
3.Expected to be availa ble for the duration of the study  and able to be contacted by  
telephone during stud y participation.
4.Male or female adults 65 to <86 y ears of age (from the 65th birthday  up to but not 
including the 86th birthday ) at enrollment.
5.Health y adults, including ad ults with preexisting stable disease, defined as disease not 
requiring significant change in therap y in the last 6 weeks or not worsening or requiring 
hospitalization within 6 months before investigational product administration, as 
determined b y medical h istory , phy sical examination, and clinical judgment of the 
investigator.
6. Vaccination with Prevnar 13  2 months prior to 
investigational product administration .

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 247.Male subjects able to father children must agree to use a highly  effective method of 
contracepti on as outlined in the protocol from the time of informed consent through at 
least 28 day s after the last dose of investigational product.
8.Female subjects of nonchildbearing potential must meet at least 1 of the following 
criteria:
a.Achieved postmenopausal s tatus, defined as follows: cessation of regular menses for 
at least 12 consecutive months with no alternative pathological or ph ysiological 
cause; status may  be confirmed by  having a nFSH level confirming the 
postmenopausal state;
b. Have undergone a document ed hy sterectomy  and/or bilateral oophorectomy ;
c.Have medically  confirmed ovarian failure .
All other female subjects (including female subjects with tubal ligations) are considered 
to be of childbearing potential.
4.2. Exclusion Criteria
Subjects with any  of the following 
characteristics/conditions will not be included in the 
study :
Stage 1
1. Investigat or site staff members directl y involved in the conduct of the study  and their 
family  members, site staff members otherwise supervised by  the investigator, or subjects
who are Pfizer emplo yees, including their family  members, directl y involved in the 
conduct of the study .
2. Participation in other studies involving investigational drug(s), vaccines, or medical 
device(s) within 28 day s prior to study  entry and/or during study  duration.  Participation 
in purely  observational studies is acceptable.
3.Evidence or history  of clinically  significant hematologic, renal, endocrine, pulmonary , 
gastrointestinal, cardiovascular, hepatic, psy chiatric, neurological, immunologic, 
metabolic, urological, dermatologic, or allergic disease (including drug allergies, but 
excluding untreated, asymptomatic, seasonal allergies at the time of dosing) or an y other 
major disease.
4.Other acute or chronic medical or ps ychiatric condition including recent (within the past 
year) or active suicidal ideation or behavior or laboratory  abnormality  that may  increase 
the risk associated with study  participation or investigational product administration or 
may interfere with the interpretation of study  results and, in the judgment of the 
investigator, would make the subject inappropriate for entry  into this study .

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 255.Baseline laboratory  test results outside of the normal reference range considered 
clinically  significant b y the investigator (see Section 6.1.1 and Section 7.4).
6.Previous vaccination ,or planned receipt through study  participation ,with any  licensed or 
investigational pneumococcal va ccine other than study  vaccine.
7.Vaccination within 12 months before investigational product administration, or planned 
receipt through stud y participation ,with diphtheria -, pertussis -, or tetanus -containing 
vaccine(s) other than study  vaccine.
8.History  of severe adverse reaction associated with a vaccine and/or severe allergic 
reaction (eg, anaph ylaxis) to any  component of the investigational products or an y other 
diphtheria toxoid–containing vaccine.
9.History  of microbiologically proven invasive disease cau sed by  S pneumoniae.
10.Subjects who receive treatment with immunosuppressive therap y, including cytotoxic 
agents or s ystemic corticosteroids, or planned receipt through the last postvaccination 
blood draw. If systemic corticosteroids have been administered short term (<14 day s) for 
treatment of an acute illness, subjects should not be enrolled into the study  until 
corticosteroid therap y has been discontinued for at least 28days before investigational 
product administration . Inhaled/nebulized, intra -articul ar, intrabursal, or topical (skin or 
eyes) corticosteroids are permitted.
11. Subjects with known or suspected immunodeficiency  or other conditions associated with 
immunosuppression, including, but not limited to,
immunoglobulin class/subclass 
deficiencies, ge neralized malignancy , human immunodeficiency  virus (HIV) infection, 
leukemia, ly mphoma, or organ or bone marrow transplant.
12. Bleeding diathesis or condition associated with prolonged bleeding that would, in the 
opinion of the investigator, contraindicate intramuscular injection.
13.Receipt of blood/plasma products or immunoglo
bulin, within 60 day s before
investigational product administration , or planned receipt through stud y participation.
14. Pregnant female subjects or breastfeeding female subjects (known or suspected).
Stage 2
1.Investigator site staff members directl y involved in the conduct of the study and their 
family  members, site staff members otherwise supervised by  the investigator, or subjects 
who are Pfizer emplo yees, including their family  member s,directly involved in the 
conduct of the stud y.
2. Participation in other studies involving investigational drug(s), vaccines, or medical 
device(s) within 28 prior to study  entry  and/or during study  duration.  Participation in 
purely  observational studies is accep table.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 263.Serious chronic disorder including metastatic malignancy, severe chronic obstructive
pulmonary  disease (COPD) requiring supplemental oxy gen, end- stage renal disease with 
or without dialy sis, clinically  unstable cardiac disease, or an y other disorder that in the 
investigator’s opinion excludes the subject from participating in the study .
4.Other acute or chronic medical or ps ychiatric condition including recent (within the past 
year) or active suicidal ideation or behavior or laboratory  abnormality  that may increase 
the risk associated with study  participation or investigational product administration or 
may interfere with the interpretation of study results and, in the judgment of the 
investigator, would make the subject inappropriate for entry  into thi s study .
5.Previous vaccination with any  pneumococcal vaccine other than a single prior dose of 
Prevnar 13 ( 2 months prior to investigation product administration ) or investigational 
pneumococcal vaccine other than study  vaccines, or planned receipt through study  
participation .
6.History  of severe adverse reaction associated with a vaccine and/or severe allergic 
reaction (eg, anaph ylaxis) to any  component of the investigational products (ie, c7vPnC 
or PPSV23).
7.History  of microbiologically proven invasive disea se caused b y S pneumoniae.
8.Subjects who receive treatment with immunosuppressive therap y, including cytotoxic 
agents or s ystemic corticosteroids, or planned receipt through the last postvaccination 
blood draw. If systemic corticosteroids have been administered short term (<14 days) for 
treatment of an acute illness, subjects should not be enrolled into the study  until 
corticosteroid therap y has been discontinued for at least 28days before investigational 
product administration. Inhaled/nebulized, intra -articular, intrabursal, or topical (skin or 
eyes) corticosteroids are permitted.
9. Subjects with known or suspected immunodeficiency  or other conditions associated with 
immunosuppression, including, but not limited to, immunoglobulin class/subclass 
deficienci es, generalized malignancy, HIV infection, leukemia, ly mphoma, or organ or 
bone marrow transplant.
10. Bleeding diathesis or condition associated with prolonged bleeding that would, in the 
opinion of the investigator, contraindicate intramuscular injection.
11.Receipt of blood/plasma products or immunoglobulin, from 60 day s before 
investigational product administration , or planned receipt through stud y participation.
4.3.Temporary Delay Criteria
The following conditions are temporary  or self -limiting and a subject may be vaccinated 
and/or have blood drawn in the study  once the condition(s) has/have resolved and no other 
exclusion criteria are met.  The prevaccination immunogenicity  blood draw must occur on 
the same day  as vaccination.

PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 274.3.1. Criteria for Temporarily Delaying Vaccine Administration (Stage 1 and Stage 2: 
Visit 1)
•Febrile illness (body temperature ≥100.4 °F [≥38°C]) or other acute illness within 48 
hours before investigational product administration.
•Receipt of any inactivated vaccine within 14 days or any live vaccine within 28 days 
before investigational product administration.
•Receipt of short-term (<14 days) systemic corticosteroids. Investigational product 
administration should be delayed until systemic corticosteroid use has been discontinued for at least 28 days. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
4.3.2. Criteria for Temporarily Delaying Immunogenicity Blood Draw (Stage 1: Visit 1 
and Visit 2; Stage 2: Visits 1, 2 )
•Receipt of antibiotic therapy within 72 hours before blood draw for immunogenicity 
samples.
4.4. Lifestyle Requirements
4.4.1. Contraception
All male subjects who are able to father children and all female subjects who are of 
childbearing potential and who are, in the opinion of the investigator, sexually active and at risk for pregnancy with their partner(s) must agree to use a highly effective method of contraception consistently and correctly for at least 28 days after the dose of investigational product.  The investigator or his or her designee, in consultation with the subject, will confirm that the subject has selected an appropriate method of contraception for the individual subject and their partner from the permitted list of contraception methods (see below) and will confirm that the subject has been instructed in its consistent and correct use.  At time points indicated in the Schedule of Activities , the investigator or designee will 
inform the subject of the need to use highly effective contraception consistently and correctly and document the conversation and the subject’s affirmation in the subject’s chart (subjectsneeds to affirm their consistent and correct use of at least 1 of the selected methods of contraception).  In addition, the investigator or designee will instruct the subject to call immediately if the selected contraception method is discontinued or if pregnancy is known or suspected in the subject or the partner.
Highly effective methods of contraception are those that, alone or in combination, result in a 
failure rate of less than 1% per year when used consistently and correctly (ie, perfect use) and include the following:
1. Established use of hormonal methods of contraception associated with inhibition of 
ovulation (eg, oral, inserted, injected, implanted, transdermal) provided the subject or male subject’s female partner plans to remain on the same treatment throughout the entire CCI
PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 28study  and has been using that hormonal contraceptive for an adequate period of time to 
ensure effectiveness .
2.Correctl y placed copper -containing intrauterine device (IUD) .
3.Male condom or female condom used WI TH a separate spermicide product (ie,foam, gel, 
film, cream, or suppository ). For countries where spermicide is not available or condom 
plus sperm icide is not accepted as highl y effective contraception, this option is not 
appropriate.
4.Male sterilization with absence of sperm in the postvasectomy  ejaculate .
5.Bilateral tubal ligation/bilateral salpingectom y or bilateral tubal occlusive procedure 
(provi ded that occlusion has been confirmed in accord ance with the device’s label).
6.Female partner who meets the criteria for nonchildbearing potential, as described below :
Achieved postmenopausal status, defined as follows: cessation of regular menses for 
at least 12 consecutive months with no alternative pathological or phy siological 
cause; status may  be confirmed by  having an FSH level confirming the 
postmenopausal state;
Have undergone a documented hy sterectomy  and/or bilateral oophorectomy ;
Have medically  confirmed ovarian failure.
NOTE: Sexual abstinence, defined as completel y and persistently  refraining from all 
heterosexual intercourse (including during the entire period of risk associated with the study  
treatments) may  obviate the need for contraception O NLY if this is the preferred and usual 
lifesty le of the subject.
4.5.Sponsor ’sQualified Medical Personnel
The contact information for the sponsor's appropriately qualified medical personnel for the 
study  is documented in the study  contact list located in thesupporting study  documentation .
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, subjects are provided with a contact card. The contact card contains, 
at a minimum, protocol and investigational product identifiers, subject study numbers, 
contact information for the investigat orsite, and contact details for a contact center in the 
event that the investigat orsite staff cannot be reached to provide advice on a medical 
question or problem originating from another healthcare professional not involved in the 
subject’s participation in the study .The contact number can also be used by  investiga tor
staff if they  are seeking advice on medical questions or problems; however, it should be used
only inthe event that the established communication pathway s between the investigator site 
and the study  team are not available. It is therefore intended to augment, but not replace, the 
established communication pathway s between the 
investigator site and the study  team for 

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 29advice on medical questions or problems that may arise during the stud y.The contact 
number is not intended for use by the subject directly, and if a subject calls that number, he 
or she will be directed back to the investigator site.
5.INVEST IGATIONAL PRODUCTS
For the purposes of this study , and per International Council for Harmoni sation ( ICH)
guidelines, investigational product is defined as a pharmaceutical form of an active 
ingredient or placebo being tested or used as a reference/comparator in a clinical trial, 
including a product with a marketing authorization when used or assembled (formulated or 
packaged) in a way  different from the approved form, or when used for an unapproved 
indication, or when used to gain further information about an approved use (ICH E6 1.33) .
For this study , the investigational product s are c7vPnC, Tdap (Stage 1 only ), and PPSV23
(Stage 2 only ).
5.1.Allocation to Investigational Product
Allocation of subjects to vaccine groups will occur through the use of an interact ive response 
technology  (IRT) s ystem ( interactive Web -based response [ IWR]). The sitepersonnel will 
be required to enter or select information including but not limited to the user’s identification 
(ID)and password, the protocol number ,andthe subject number. The site personnel will 
then be provided with a randomization number and dispensable unit (DU) or container 
number when investigational product is being supplied via the I RTsystem .  The I RT sy stem 
will provide a confirmation report containing the subject number , randomization number ,and 
DU or container number assigned. The confirmation report must be retained in the site files.
The study -specific I RT reference manual will provide the contact information and further 
details on the use of the IRT system .
5.2.Blinding of the Site Personnel
This is an observer -blind ed study , as the appearance of c7 vPnC ,Tdap , and PPSV23 will not 
be matched. Prefilled syringes will be packaged in blinded cartons .  The study  staff 
administering the vaccine will be unblind ed, but all other study  personnel including the 
principal investigator (PI), and the subject, will be blinded. The PIwill assign the 
responsibility  of unblinded administrator to persons who will not participate in the evaluation 
of an y study subject. More than 1 unblinded administrator may  be assigned. A member of 
the study  site staff or clinic pharmacy
 should fulfill this role. Contact between the unblinded 
administrator and study  subjects should be kept to a minimum. The investigator, study 
coordina tor, and any  site staff other than the unblinded administrator must not be allowed to 
know the investigational product assigned to an y study subject and must not be allowed to 
see the investigational product prefilled s yringes .

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 305.3.Blinding of the Sponsor
In Stage 1 ,certain sponsor staff outside of the core study  team will monitor unblinded safet y 
data for events that trigger stopping rules or for unexpected safet y findings as the data are 
collected. Sponsor core study  team members will remain blinded to vacc ine 
assigned/received at the subject level, following the principles outlined in ICH E9 guideline 
on Statistical Principles for Clinical Trials, Section 2.3.1,60until the analy sis of all available 
safet y data 1 month after vaccination. Study  team members will review analy ses in an 
unblinded manner.
In Stage 2, c ertain sponsor staff outside of the core stu dy team will monitor unblinded safet y 
data prior to the 1 -month postvaccination anal ysis as the data are collected.   Sponsor core 
study  team members will remain blinded to vaccine a ssigned/received at the subject level 
until the analy sis of all available safety  and immunogenicity data 1 month after vaccination.   
Study  team members will review analy ses in an unblinded manner.
In both stages, sponsor personne l directly  involved in evaluating subject data will be blinded 
to vaccine assignment as described above , following the principles outlined in I CH E9 
guideline on Statistical Principles for Clinical Trials.60  Adata blinding plan will be created 
to describe the blinding requirements and unblinding events. The plan to control distribution 
of unblinded data among designated Pfizer personnel and core study  team members will be 
specified in the data dissemination p lan.  Laboratory  personnel performing the immunologic 
assay s will be blinded until the 
study  database has been locked and unblinded.
5.4.Breaking the Blind
The study  will be subject and investigator blinded.
At the initiation of the study , the 
investigator site will be instructed on the method for 
breaking the blind for an individual subject .  The method will be an electronic process.  
Blinding codes should be broken only in exceptional circumstances when knowledge of the 
actual treatment code is absolutely  essential for further management of the subject.
Investigators are encouraged to discuss with a member of the stud y team if they believe that 
unblinding is necessary . When the blinding code is broken, the reason must be fully  
documented and entered on the c ase report form (CRF) .
5.5.Subject Compliance
Thedose of investigational product will be administered b y the appropriately designated 
study  staff at the investigator site.
5.6.
Investigational Product Supplies
c7vPnC, Tdap (control for Stage 1), and PPSV23 (contro lfor Stage 2) will be provided by  
the sponsor to the study  sites
.
Study  vaccines will be packed and labeled as investigational product in accordance with 
current guidelines andapplicable local and legal regulatory  requirements.  The formulation 
of the in vestigational products is described below.

PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 315.6.1. Dosage Form(s) and Packaging
c7vPnC contains saccharides of the capsular antigens to S pneumonia serotypes 8, 10A, 11A, 
12F, 15B, 22F, and 33F individually conjugated to CRM 197.   
  
 
 c7vPnC will be supplied by 
the sponsor to the sites as packaged single-use prefilled syringes and labeled according to local regulatory requirements.
Tdap is a sterile isotonic suspension of tetanus and diphtheria toxoids and pertussis antigens 
adsorbed on aluminum phosphate, for intramuscular injection. Tdap will be provided by the sponsor to the sites as packaged single-use prefilled syringes and labeled according to local regulatory requirements.
PPSV23 is a licensed commercial product (Pneumovax, Merck) and is a clear, sterile solution 
consisting of a mixture of purified capsular polysaccharides from 23 serotypes of S pneumoniae: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 
20, 22F, 23F, and 33F.  The vaccine is formulated to contain 25 μg of each of the 23 purified 
polysaccharide serotypes per 0.5-mL dose of vaccine in an isotonic saline solution containing 0.25% phenol as a preservative.  PPSV23 will be supplied by the sponsor to the sites as packaged single-use prefilled syringes and labeled according to local regulatory requirements.
5.6.2. Preparation and Dispensing
See the investigational product manual for instructions on how to prepare the investigational 
product for administration.  Investigational product should be prepared and dispensed by an appropriately qualified and experienced member of the study staff (eg, physician, nurse, physician’s assistant, nurse practitioner, pharmacy assistant/technician, or pharmacist) as allowed by local, state, and institutional guidance.
Investigational product will be prepared by qualified unblinded site personnel according to 
the investigational product manual.
5.7. Administration
All subjects will receive a single dose (0.5 mL) of investigational product intramuscularly 
into the deltoid muscle, preferably in the nondominant arm, at Visit 1.  The injection will be administered to the blinded subject by the designated unblinded administrator.
Standard vaccination practices must be observed and vaccine must not be injected into blood 
vessels.  Appropriate medication and other supportive measures for management of an acute hypersensitivity reaction should be available in accordance with local guidelines for standard 
immunization practices.
Administration of investigational products should be performed by an appropriately 
qualified, Good Clinical Practice (GCP)-trained, and vaccine-experienced member of the CCI
PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 32study staff (eg, physician, nurse, physician’s assistant, nurse practitioner, pharmacist, or 
medical assistant) as allowed by local, state, and institutional guidance.
Investigational product administration details will be recorded on the CRF.
5.8. Investigational Product Storage
The investigator or an approved representative (eg, pharmacist, unblinded administrator) will 
ensure that all investigational products are stored in a secured area with controlled access under required storage conditions and in accordance with applicable regulatory requirements.
Investigational products should be stored in their original containers and in accordance with 
the labels.
c7vPnC, Tdap, and PPSV23 will be shipped to the study site after required regulatory and 
legal documents have been received by the sponsor.
 
Any storage conditions stated in the SRSD (c7vPnC IB, Tdap USPI, and PPSV23 USPI) will
be superseded by the storage conditions stated on the product label.
Site systems must be capable of measuring and documenting (for example, via a log), at a 
minimum, daily minimum and maximum temperatures for all site storage locations (as applicable, including frozen, refrigerated, and/or room-temperature products).  This should be captured from the time of investigational product receipt throughout the study.  Even for continuous-monitoring systems, a log or site procedure that ensures active evaluation for excursions should be available.  The intent is to ensure that the minimum and maximum temperature is checked each business day to confirm that no excursion occurred since the last evaluation and to provide the site with the capability to store or view the minimum/maximum temperature for all nonworking days upon return to normal operations.  The operation of the temperature-monitoring device and storage unit (for example, refrigerator), as applicable, should be regularly inspected to ensure they are maintained in working order.
Any excursions from the product label storage conditions should be reported to Pfizer upon 
discovery. The site should actively pursue options for returning the product to the storage conditions described in the labeling, as soon as possible.  Deviations from the storage requirements, including any actions taken, must be documented and reported to Pfizer.
Once an excursion is identified, the investigational product must be quarantined and not used 
until Pfizer provides permission to use the investigational product.  It will not be considered a protocol deviation if Pfizer approves the use of the investigational product after the temperature excursion. Use of the investigational product prior to Pfizer approval will be 
considered a protocol deviation. Specific details regarding information the site should report 
for each excursion will be provided to the site.CCI
PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 335.9. Investigational Product Accountability
The designated staff at the investiga torsite must maintain adequate records documenting the 
receipt, use, loss, or other disposition of the investigational product supplies.  All 
investigational products will be accounted for using a drug accountability  form/record.
Used needles and s yringes should be disposed of according to local practice. Empty  outer 
investigational product containers must be retained until reviewed by  the sponsor's site staff 
and then may  be destroy ed after the sponsor’s site staff has performed accountability .
Investigational product return/destruction must be documented on the accountability  log.
5.9.1. Destruction of Investigational Product Supplies
The sponsor or designee will provide guidance on the destruction of un used investigational 
product (eg, at the site). If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materials are destroy ed in compliance with applicable 
environmental regulations, institutional policy , and any  special instructions provided by  
Pfizer ,and all destruction must be adequatel y documented.
5.10. Prior Vaccination (Stage 2 Only)
The d ate of the Prevnar 13 vaccination received prior to study  enrollment must be recorded 
in the CRF .
5.11. Concomitant Treatment(s)
5.11.1. Prohibited Concomitant Treatments
Stage 1 and Stage 2 subjects:
oReceipt of blood/plasma products, immunoglobulins, and/or immunosuppressive 
therap y (including a 14-day consecutive course of sy stemic co rticosteroids) is 
prohibited until after Visit 2 of the study .
oReceipt of an y nonstudy  investigational vaccines, drugs ,or medical devices is 
prohibited during subject participation in the study.
oReceipt of nonstudy pneumococcal vaccine is prohibit ed during subject participation 
in the study .
oReceipt of a ny licensed vaccine, with the exception of licensed inactivated influenza 
vaccin e (see P ermitted Concomitant Treatments) ,is prohibited until after Visit 2 of 
the study .
Stage 1 s ubjects only :  Rece ipt of nonstudy  vaccines containing tetanus, diphtheria, or 
pertussis is prohibited during subject participation in the study .

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 345.11.2. Permitted Concomitant Treatments (Stage 1 and Stage 2 S ubjects)
Licensed inactivated influenza vaccine may  be given >14 day s prio r to or after 
investigational product administration. If medically necessary (eg, pandemic), influenza
vaccine may  be given at any  time.
Prescription and nonprescription medications, vitamins, minerals, and herbal remedies 
are permitted during subject par ticipation in the study .
The use of proph ylactic antipy retic medication, while permitted, is not recommended on 
the day  prior to vaccination or the day  of the vaccination.
Inhaled/nebulized, topical (skin, ey es,or ears), or localized injections of cortico steroids 
(eg, intra -articular or intrabursal administration) are permitted during subject 
participation in the study .
5.11.3. Recording Concomitant Treatments
The name and date of administration for all nonstudy  vaccinations received from the time of 
signing of the informed consent document to Visit 3 (Stage 1) or Visit 4(Stage 2) will be 
collected and recorded in the CRF (per Section 5.11.1 and Section 5.11.2).
Medications taken to treat SAEs or NDCMCs from the signing of the 
informed consent 
document to Visit 3 (Stage 1) or Visit 4 (Stage 2) will be recorded in the CRF.
6.STUDY PROCEDURES
The study procedures are summarized in the Schedule of Activities .  The day  of vaccination 
is considered to be Day  1.
6.1. S tage 1 Study Procedures
6.1.1. Screening (14 to 2 Days Prior to V accination) – Clinic Visit
Subjects will be screened 2 to 14days prior to administration of the investigational product 
to confirm that they  meet the subject selection criteria for the study . If the time between 
screening and vaccination is >14daysbut 28daysas a result of unexpected delay s 
(eg,delay ed vaccine shipment), then qualified subjects do not require rescreening if the 
screening visit safet y laboratory  results and review of recent medical history  meet the 
eligibility  criteria.
The following procedures will be performed:
Obtain written informed consent before performing any study -specific procedures.
Assign subject number via the IRT.
Obtain and record the subject demograph y (sex, birth date, ethnicity , race, racial 
designation)
.

PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 35•Obtain and record any medical history of clinical significance.
•Perform physical examination evaluating any clinically significant abnormalities within 
the following body systems: general appearance; skin; head, eyes, ears, nose, and throat; 
heart; lungs; abdomen; musculoskeletal; extremities; neurological; and lymph nodes.  Abnormal results will be recorded in the CRF.  Vital signs (sitting blood pressure, pulserate, and respiratory rate) should also be assessed and recorded in the source documents.
•Record nonstudy vaccinations and concomitant medications as described in
Section 5.11.3 .
•Ensure and document that all of the inclusion criteria and none of the exclusion criteria 
are met.
•Obtain a blood sample for  hematology and chemistry.  Subjects with 
abnormal laboratory results ( Section 7.4 ) outside of normal reference ranges that are 
considered to be clinically significant by the investigator will not be eligible forrandomization.
•If abnormal laboratory parameters are reported at screening and the investigator 
believes the results to be erroneous or represent stable Grade 1 abnormalities
(seeSection 7.4 ), a retest of the abnormal laboratory parameters may be conducted.
Subjects with stable Grade 1 abnormalities may be considered eligible at the discretion of the investigator.  A “stable” Grade 1 laboratory abnormality is defined 
as a report of Grade 1 on an initial blood sample that remains ≤Grade 1 upon repeat
testing on a second sample from the same subject.
•Record AEs as described in Section 8 .
•Remind the subject to use appropriate contraceptives until 28 days after vaccination, if 
applicable.
•The investigator or an authorized designee completes the CRF.
6.1.2. Visit 1 (Day 1; Day of Vaccination) – Clinic Visit
•Prior to vaccination:
•Ensure and document that all of the inclusion criteria and none of the exclusion 
criteria are met and that none of the temporary delay criteria are met.
•Measure and record the subject’s oral temperature ( °F/°C).
•Perform urine pregnancy test for female subjects of childbearing potential
(seeSection 7.1 ).
•Perform a contraception check (see Section 4.4.1 ), if applicable.CCI
PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 36Record nonstud y vaccinations and concomitant medications as described in
Section 5.11.3.
Assign randomization number and investigational product container number via the 
IRT.  This must be the last step before proceeding .  The unblinded site staff member 
will prepare the investigational product according to the investigational pr oduct 
manual.
After randomization :
Collect a blood sample of approximatel y 50 mL for immunogenicity  assessments
prior to vaccination.
The u nblinded administrator willadminister a single 0.5 -mL injection of 
investigational product into the deltoid muscle ( preferabl y in the nondominant arm).
Blinded site staff willobserve the subject for at least 30 minutes after investigational 
product administration for an y acute reactions.  Record an y acute reactions on the AE 
CRF and on a nSAE form as applicable.
Issue the subject a measuring device to measure injection site reactions and a digital 
thermometer and provide instructions on their use.
Issue the subject an e -diary  and provide instructions on its use and completion.  Ask 
the subject to complete the e
-diary  from Day 1 to Day  14, with Day 1 being the day  
of vaccination.
Ask the subject to contact the site staff or investigator immediately during the 14 -day 
postvaccination period if he or she experiences fever >104.0 F (>40.0C) or a 
Grade 3 local reaction (ie, redness or swelling at the injection site measuring 
21 measuring device units [ 10.5 cm], or severe injection site pain [prevents daily  
activity ]
)to determine if the event requires further assessment by  the investigator.
Subjects will also be instructed t o contact site staff if they  experience an y possible 
Grade 4 prompted local reaction or systemic event (refer to Section 7.2.3) or any  
severe nonprompted AE or an y SAE during the 14 -day postvaccination period .
Remind the subject that study  staff may  assess him or her to obtain additional 
information on Grade 3 ev
ents entered into the e- diary .
Ask the subject to contact the investigator or site staff immediatel y if an y significant
illness ormedical event (eg, emergency  room visit or hospitalization) occur sduring 
the study  period.
Remind the subject to use appropriate contraceptives until 28 day s after vaccination, 
if applicable.

PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 37•Record AEs as described in Section 8 .
•The investigator or an authorized designee completes the CRF and updates the 
investigational product accountability records.
•The investigator or appropriately qualified designee reviews the e-diary data online at 
frequent intervals (daily is optimal) for the 14 days following vaccination to evaluate 
subject compliance and as part of the ongoing safety review.
6.1.3. Visit 2 (Month 1; 28 to 35 Days After Vaccination) – Clinic Visit
•Ensure and document that the subject continues to be eligible for the study and that none 
of the temporary blood draw delay criteria are met.
•Perform a contraception check (see Section 4.4.1 ), if applicable.
•Record nonstudy vaccinations and concomitant medications as described in
Section 5.11.3 .
•
•Collect a blood sample of approximately 50 mL for immunogenicity assessments.
•Review the subject’s e-diary data and collect the e-diary. Collect stop dates of any 
e-diary events ongoing on the last day that the e-diary was completed and record stop 
dates in the CRF.
•Determine whether any AEs, SAEs, or NDCMCs have occurred since Visit 1 and follow 
up on any previously reported ongoing AEs, SAEs, or NDCMCs to determine the 
outcome (ie, record stop dates or confirm if they are still continuing) and record as described in Section 8 .
•Remind the subject to contact the investigator or site staff immediately if any significant 
illness or medical event (eg, emergency room visit or hospitalization) occurs during the study period.
•The investigator or an authorized designee completes the CRF.
6.1.4. Visit 3 (Month 6; 168 to 196 Days After Vaccination) – Telephone Contact
•Record nonstudy vaccinations and medications as described in Section 5.11.3 .
•Determine whether any NDCMCs or SAEs have occurred since Visit 2 and follow up on 
any previously reported ongoing AEs, SAEs, or NDCMCs to determine the outcome 
(ie, record stop dates or confirm if they are still continuing) and record as described in Section 8 .
•The investigator or an authorized designee completes the CRF.CCI
PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 386.2. S tage 2 Study Procedures
6.2.1. Visit 1 ( Day 1; Day of Vaccination) –Clinic Visit
Prior to vaccination:
Obtain written informed consent before performing any study -specific procedures.
Assign asubject number via the I RT.
Obtain and record the subject demograph y (sex, birth date, ethnicity , race, racial 
designation).
Obtain and record an y medical history  of clinical significance.
Obtain and recor d the date of Prevnar 13 vaccination received prior to study  
enrollment.
Perform ph ysical examination evaluating an y clinically significant abnormalities 
within the following body  systems: general appearance; skin; head, ey es, ears, nose, 
and throat; heart; lungs; abdomen; musculoskeletal; extremities; neurological; and 
lymph nodes.  Abnormal results willbe recorded in the CRF . Vital signs (sitting 
blood pressure, pulse rate, and respiratory  rate) should also be assessed and recorded 
in the source documen ts.
Measure and record the subject’s prevaccination oral temperature ( F/C).
Record nonstud y vaccinations and concomitant medications as described in
Section 5.11.3 .
Ensure and document that a ll of the inclusion criteria and none of the exclusion 
criteria are me tand that none of the temporary  delay  criteria are met .
Assign arandomization number and investigational product container number via the 
IRT. This must be the last step before vaccin ating the subject.   The unblinded site 
staff member will prepare the investigational product according to the investigational 
product manual.
After randomization :
Collect a blood sample of approximatel y 50 mL for immunogenicity  assessments
prior to vaccina tion.
The u nblinded administrator willadminister a single 0.5 -mL injection of 
investigational product into the deltoid muscle (preferabl y in the nondominant arm).

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 39Blinded site staff willobserve the subject for at least 30 minutes after investigational 
product administration for any  acute reactions.  Record any  acute reactions on the AE 
CRF and on a nSAE form as applicable.
Issue the subject a measuring device to measure injection site reactions and a digital 
thermometer and provide instructions on their u se.
Issue the subject an e -diary  and provide instructions on its use and completion.  Ask 
the subject to complete the e- diary  from Day 1 to Day  14, with Day 1 being the day  
of vaccination.
Ask the subject to contact the site staff or investigator immediate ly if he or she 
experiences fever >104.0 F (>40.0C) or Grade 3 local reaction (ie, redness or 
swelling at the injection site measuring 21 measuring device units [ 10.5 cm], or 
severe injection site pain [prevents daily  activity ]
)to determine if the even t requires 
further assessment b y the investigator.
Subjects will also be instructed to contact site staff if they  experience an y possible 
Grade 4 prompted local reaction or systemic event (refer to Section 7.2.3).
Remind the subject that study  staff may  assess him or her to obtain additional 
information on Grade 3 events entered into the e- diary .
Ask the subject to notify  the investigator or site staff immediatel y if an y significant 
illness or medical event (eg, emergency  room visit or hospitalization) occur s during 
the study  period .
Remind the subject to use appropriate contraceptives until 28 day s after vaccination, 
if applicable.
Record AEs as described in Section 8.
The investigator or an authorized designee completes the CRF and updates the 
investigational product accountability  records.
The investigator or appropriately  qualified designee reviews the e -diary  data online at 
freque nt intervals (dail y is optimal) for the 14 days following vaccination to evaluate 
subject compliance and as part of the ongoing safety  review.
6.2.2. Visit 2 
(Month 1; 28 to 35 D ays A fter Vaccination) – Clinic Visit
Ensure and document that the subject 
continues to be eligible for the stud y and that none 
of the temporary  blood draw delay criteria are met.
Perform a contraception check (see Section 4.4.1), if applicable.

PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 40•Record nonstudy vaccinations and concomitant medications as described in
Section 5.11.3 .
•Collect a blood sample of approximately 50 mL for immunogenicity assessments.
•Review the subject’s e-diary data and collect the e-diary. Collect stop dates of any 
e-diary events ongoing on the last day that the e-diary was completed and record stop 
dates in the CRF.
•Determine whether any AEs, SAEs, or NDCMCs have occurred since Visit 1 and follow 
up on any previously reported ongoing AEs, SAEs, or NDCMCs to determine the 
outcome (ie, record stop dates or confirm if they are still continuing) and record as described in Section 8 .
•Remind the subject to contact the investigator or site staff immediately if any significant 
illness or medical event (eg, emergency room visit or hospitalization) occurs during the study period.
•The investigator or an authorized designee completes the CRF.
6.2.3. Visit 3 (Month 6; 168 to 196 Days After Vaccination) – Telephone Contact
•Record nonstudy vaccinations and concomitant medications as described in
Section 5.11.3 .
•Ensure and document that the subject continues to be eligible for the study.
•Determine whether any NDCMCs or SAEs have occurred since Visit 2 and follow up on 
any previously reported ongoing AEs, SAEs, or NDCMCs to determine the outcome 
(ie, record stop dates or confirm if they are still continuing) and record as described inSection 8 .
•The investigator or an authorized designee completes the CRF.
6.2.4. Visit 4 (Month 12; 350 to 378 Days After Vaccination) – Clinic Visit
•Ensure and document that none of the temporary blood draw delay criteria are met.
•Record nonstudy vaccinations and concomitant medications as described in
Section 5.11.3 .
•
•Determine whether any SAEs or NDCMCs have occurred since Visit 3 and follow up on 
any previously reported AEs, SAEs, or NDCMCs to determine the outcome (ie, record 
stop dates or confirm if they are still continuing) and record as described in Section 8 .
•The investigator or an authorized designee completes the CRF.CCI
PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 416.3. Unscheduled Visits (Stage 1 and Stage 2)
If the subject reports redness or swelling at the injection site measuring 21measuring 
devic e units (10.5 cm), severe injection site pain, or fever >104.0 F (>40.0C) during the 
14-day postvaccination period, a telephone contact must occur as soon as possible between 
the investigator or appropriately  qualified designee and subject to assess if a n unscheduled 
site visit is required.  A site visit must be scheduled as soon as possible to assess the extent of 
the reaction unless any of the following is true :
The subject is unable to attend the unscheduled visit
.
The reaction is no longer present at the time of the telephone contact.
The subject recorded an incorrect value in the e
-diary  (confirmation of an e -diary  data 
entry  error).
The PI or authorized designee determined it was not needed.
This telephone contact will be recorded in the subject’s source documentation and the CRF.
If the subject is unable to attend the unscheduled visit, or the PI  or authorized designee 
determined it was not needed, an y ongoing reactions must be assessed at Visit 
2.
During the unscheduled visit, t he reactions should b e assessed b y the investigator or a 
medically  qualified member of the stud y staff such as a study ph ysician or a study  nurse, as 
applicable to the investigator’s local practice, who will:
Measure oral temperature ( F/C).
Measure minimum and maximum diamet ersof redness (if present).
Measure minimum and maximum diameter sof swelling (if present).
Assess injection site pain (if present) in accordance with the grades provided in 
Section 7.2.3.1.
Assess for other findings associated with the reaction (eg ,lymphadenopathy) and record 
on the AE page of the CRF, if appropriate .
The investigator or an authorized designee will complete the unscheduled visit assessment
page of the CRF.
Subjects will also be instructed to contact site staff if they  experience an y possible Grade 4 
prompted sy stemic event (ie ,emergency  room visit or hospitalization for headache, fatigue, 
muscle pain, or joint pain) or local reaction (ie, necrosis, exfoliative dermatitis, or 
emergency  
room visit/hospitalization for injection site pain) within 14 day s after vaccination.  Study  
staff may  contact the subject to obtain additional information on Grade 3 events entered into 

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 42the e -diary .  Lastly , subjects will be instructed to contac t the site to report any  significant 
illness, medical event, or hospitalization that occurs during the study  period.  The sit e should 
determine if an unscheduled visit to further evaluate the event is warranted in all such cases.
6.4.Subject Withdrawal
An inve stigator and/or sponsor can withdraw a subject from the study  if deemed appropriate.  
In addition, if a subject fails to continue to meet the inclusion criteria, new information 
becomes available that would exclude the subject , or the subject develops a co ndition or 
situation that would meet exclusion criteria ,the subject may  be considered for withdrawal.
Reasons wh y a subject may discontinue or be withdrawn from the study include, but are not 
limited to ,failure to meet entrance criteria (screening failur e), AE, death, pregnancy , 
protocol deviation , lost to follow -up, no longer willing to participate in the study , study  
terminated b y the sponsor, or an y other reason.  Subjects who have received the 
investigational product will not be replaced ,regardless of the reason for withdrawal.
The investigator should capture the reason for withdrawal in the database for all subjects and 
a 6-month postvaccination follow -up telephone contact for the collection of safet y 
information should be completed for all subjects who have been withdrawn after 
administration of investigational product.
6.4.1. Withdrawal of Consent
Subjects who request to discontinue after receipt of investigational product will remain in the 
study  and must continue to be followed for protocol -specified fol low-up procedures.  The 
only exception to this is when a subject specifically  withdraws consent for any  further 
contact with him or her or persons previously  authorized by  the subject to provide this 
information. Subjects should notify  the investigator in writing of the decision to withdraw 
consent from future follow -up, whenever possible.  The withdrawal of consent should be 
explained in detail in the medical records b y the investigator and entered on the appropriate 
CRF page.  I n the event that vital sta tus (whether the subject is alive or dead) is being 
measured, publicl y available information should be used to determine vital status only  as 
appropriatel y directed in accordance with local law.
6.4.2. Lost to Follow -up
All reasonable efforts must be made to loca te subjects to determine and report their ongoing
status. This includes follow
-up with persons authorized by  the subject as noted above. Lost
to follow -up is defined by  the inabilit y to reach the subject after a minimum of 2 documented
phone calls, faxes , or emails as well as lack of response by  the subject to 1 registered mail
letter. All attempts should be documented in the subject’s medical records. If it is 
determined that the subject has died, the site will use locally  permissible methods to obtain
the date and cause of death. If the investigator’s use of a third -party representative to assist 
in the follow -up portion of the study  has been included in the subject’s informed consent, 
then the investigator may use a sponsor- retained third -party repre sentative to assist site staff 
with obtaining the subject’s contact information or other public vital status data necessary  to 
complete the follow -up portion of the study . The site staff and representative will consult 

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 43publicly  available sources, such as public health registries and databases, in order to obtain 
updated contact information. If, after all attempts, the subject remains lost to follow -up, then 
the last -known- alive date as determined by  the investigator should be reported and 
documented in th e subject’s medical records.
Subjects may withdraw from the study  at any  time at their own request, or they  may  be 
withdrawn at an y time at the discretion of the investigator or sponsor for safety (see also 
Withdrawal From the Study  Due to Adverse Events ,Section 8.1.3) or behavioral reasons, or 
the inability  of the subject to comply  with the protocol -required schedule of study  visits or 
procedures at a given study  site.
If a subject does not r eturn for a scheduled visit, every  effort should be made to contact the 
subject.  All attempts to contact the subject and information received during contact attempts 
must be documented in the subject’s medical record.  In an y circumstance, every  effort 
should be made to document subject outcome, if possible.  The investigator should inquire 
about the reason for withdrawal, request that the subject return for a final visit, if applicable, 
and follow up with the subject regarding an y unresolved AEs.
If the s ubject withdraws from the study , and also withdraws consent for disclosure of future 
information, no further evaluations should be performed, and no additional data should be 
collected.  The sponsor may  retain and continue to use any  data collected bef ore such 
withdrawal of consent.
7.ASSESSMENTS
Every  effort should be made to ensure that the protocol -
required tests and procedures are 
completed as described. However ,it is anticipated that from time to time there may  be 
circumstances outside of the control o f the investigator that may  make it unfeasible to 
perform the test. In these cases the investigator will take all steps necessar y to ensure the 
safet y and well -being of the subject. When a protocol -required test cannot be performed ,the 
investigator will document the reason for this and any corrective and preventive actions that 
heor she has taken to ensure that normal processes are adhered to as soon as possible. The 
study  team will be informed of these incidents in a timely  manner .
For samples being c ollected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .
7.1.Pregnancy Testing
For female subjects of childbearing potential, a urine pregnancy  test, with sensitivity  of at 
least 25 mIU/mL , will be performed immediately  before administration of theinvestigational 
product .  A negative pregnancy  test result is required before the subject may receive the 
investigational product. Pregnancy  tests may  also be repeated if requested by  institutional 
review boards (IRBs)/ethics committees (ECs) or if required b y local regulations. In the case 
of a positive confirmed pregnancy at Visit 1
, the subject will be withdrawn from 
administration of investigational product and from the study .  In the case of a positive 

PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 44confirmed pregnancy after administration of investigational product, the subject may remain 
in the study for safety monitoring.
7.2. Safety Parameters
Safety parameters will be assessed as described in the Schedule of Activities , Section 6 , and 
below.
A medical history, physical examination, and measurement of oral temperature will be 
performed on all subjects prior to vaccination to determine subject eligibility and to establish a clinical baseline. Significant medical history and observations from the physical examination and temperature measurement will be documented and recorded in the CRF.
Acute reactions within the first 30 minutes after investigational product administration will 
be assessed and documented as an AE or SAE, as appropriate, in the CRF.
Prompted e-diary events, including local reactions and systemic events that occur in the 
14 days after investigational product administration at Visit 1, are graded as described inSection 7.2.3 .  In addition, safety laboratory testing as described in Section 7.4 will be 
performed in Stage 1.  Furthermore, AEs, SAEs, and NDCMCs will be collected as defined inSection 8 .
 
 
 
 
 
 
 
 
 CCI
PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 45 
 
 
 
 
 
 
 
 
 
  
 
   
 
 
 CCI
PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 467.2.2. Subject Electronic Diary
The subject will be asked to monitor and record local reactions, systemic events, fever ,and 
antipy retic/pain medication used to treat s ymptoms, each evening for 14 days following 
vaccination (Day  1 through Day  14, where Day  1 is the day  of vaccination) on a sy stem that 
uses a personal digital assistant (PDA) or other technology .  This s ystem, hereafter referred 
to as the subject’s e -diary, allows recording of these assessments onl y within a fixed time 
window, thus providing the accurate representation of the subject’s experience at that time.  
Data on local reactions, systemic events, fever, and antipy retic/pain medication used to treat 
symptoms reported on the e -diary  will be transferred electronicall y to the e -diary  vendor, 
where they  will be available for review by  investigators, their appropriately  qualified 
designees, and sponsor staff at all times via an i nternet -based portal.  At intervals agreed to 
by the vendor and Pfizer, these data will be transferred electronically to Pfi zer for anal ysis 
and reporting.
These data do not need to be reported b y the investigator in the CRF.  However, if a subject 
withdraws because of prompted events reported in the e -diary , the event(s) should be 
recorded on the AE page of the CRF, regardless of whether the investigator considers the 
event(s) to be clinically  significant.
Investigators (or appropriately qualified designee s) are required to review the e -diary  data 
online at frequent intervals ( daily is optimal) to evaluate subject compliance and as part of 
the ongoing safet y review (see Stopping Rules in Section 7.2.1).
The investigator or designee must contact the subject in order to obtain stop dates for an y 
reactions ongoing on the last day  that the e -diary  was completed.  The stop dates should be 
entered in the CRF at Visit 2.
7.2.3.
Grading Scale for Prompted Events
The grading scales used in this study  to asse ss AE s as described below are based on concepts 
outlined in the Food and Drug Administration (FDA) Center for Biologics Evaluation and 
Research (CBER) guidelines on toxicity  grading scales for health y adult volunteers enrolled 
in preventive vaccine clinica l trials.61
7.2.3.1. Local Reactions
From Day 1 to Day 14, where Day  1 is the day  of vaccination, subjects will be asked to 
assess redness, swelling, 
and pain at the injection site and to record the s ymptoms in the 
e-diary  in the evening.  Redness and swelling will be measured and recorded in measuring 
device units (range: 1 to 21+), and then categorized during anal ysis as mild, moderate, or 
severe based on the grading scale in Table 1below.  Measuring device units can be converted 
to centi meters according to the following scale: 1 measuring device unit = 0.5 cm.  Pain at 
the vaccine injection site will be assessed b y the subject as mild, moderate ,or severe 
according to the grading scale in Table 1.  A subject with a severe (Grade 3 or above) local 
reaction will be prompted to contact the investigator to assess the reaction and perform an 
unscheduled assessment or visit as appropriate.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 47Only  an investigator is able to classify  a subject’s local reaction as Grade 4, after ph ysical 
examination of the subject or documentation from another medically  qualified source 
(eg,emergency  room or hospital record) or, in the case of pain at the injection site only , 
telephone contact with the subject.   If a subject experiences a Gr ade4 local reaction, the 
investigator must immediately  notify  the sponsor. Site staff will educate the subject 
regarding signs and s ymptoms that would prompt site contact.
The procedure for notification of the sponsor is provided in the study  refere nce m anual 
(SRM) or equivalent.
Table 1. Grading Scales for Local Reactions
Mild
Grade 1Moderate
Grade 2Severe
Grade 3aGrade 4b
Redness
(synonym with 
erythema)5 to 10 measuring 
device units 
=
2.5 to 5.0 cm11 to 20 measuring 
device units
=
5.5 to 10.0 cm21 measuring 
device units
=
10.5 cmNecrosis or exfoliative 
dermatitis
Swelling
(synonym with 
edema)5 to 10 measuring 
device units
=
2.5 to 5.0 cm11 to 20 measuring 
device units
=
5.5 to 10.0 cm21 measuring 
device units
=
10.5 cmNecrosis
Pain at injection site Does not interfere 
with activityInterferes with 
activityPrevents daily 
activitycEmergency room visit 
or hospitalization
Abbreviations: CRF = case report form; e -diary = electronic diary.
Note: If the size o f the redness and/or sw elling falls between 2 measuring device units, the higher measuring 
device unit number will be recorded in the e -diary.
a.Subjects experiencing Grade 3 local reaction swill be asked to contact the study site.  In the event that the 
subject does not call, the investigator will call the subject.
b.Grade 4 assessment should be made by the investigator. Grade 4 w ill not be collected in the e -diary but 
will be collected as an AE on the CRF.  The severity of the local reaction should be graded using the AE 
severity grading scale in Section 8.3.
c.Prevents daily activity, ie, results in missed days of work or sc hool or is otherwise incapacitating.
7.2.3.2. Systemic Events
From Day 1 to Day 14, where Day  1 is the day  of vaccination, subjects will be asked to 
assess headache, fatigue, muscle pain, and joint pain and to record the sy mptoms in the 
e-diary  in the evening.  T he sy mptoms will be assessed by  the subject as mild, moderate ,or 
severe according to the grading scale in Table 2below. Subjects will also be instructed to 
contact site staff if they  experience any possible Grade 4 prompted s ystemic event 
(ie,emergency  room visit or hospitalization for headache, fatigue, muscle pain, orjoint pain) 
within 14 day s after vaccination.  Study  staff may  also contact the subject to obtain additional 
information on Grade 3 events entered into the e -diary.
Only  an investigator is able to classify  a subject’s sy stemic event as Grade 4, after ph ysical 
examination of the subject or documentation from another medically  qualified source 

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 48(eg,emergency  room or hospital record) or telephone contact with the su bject.  If a subject 
experiences a Grade 4 systemic event, the investigator must immediately notify the sponsor .
The procedure for notification of the sponsor is provided in the SRM or equivalent.
Table 2. Grading Scales for Systemi c Events
Mild
Grade 1Moderate
Grade 2Severe
Grade 3aGrade 4b
Fatigue
(synonym with
tiredness)Does not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospitalization
Headache Does no t interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospitalization
Muscle pain Does not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room v isit 
or hospitalization
Joint pain Does not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospitalization
Abbreviations: CRF = case report form; e -diary = electronic diary .
a. P revents daily routine activity ,ie, results in missed days of work or school or is otherw ise incapacitating.
b.Grade 4 assessment should be made by the investigator; Grade 4 w ill not be collected in t he e-diary but will 
be collected as an AE on the CRF. The severity of the systemic event should be graded using the AE 
severity grading scale in Section 8.3.
7.2.3.3. Fever
In order to record informa tion on fever, a digital thermometer will be given to the subject 
with instructions on how to measure oral temperature at home.  Temperature will be 
collected in the evening daily  for 14 day s following vaccination (Day s 1 to 14, where Day  1 
is the day  of vaccination) and at an y time during the 14 day s that fever is suspected.  Fever is 
defined as an oral temperature of 100.4F (38.0C).  The highest temperature for each day  
will be recorded in the e -diary .  In the event of a fever on Day  14, temperature w ill be 
collected dail y until fever has resolved (1 day of temperature <100.4
F [<38.0C]) in order to 
collect a stop date in the CRF.  A subject with a fever >104.0 F (>40.0
C) will be prompted 
to contact the investigator to assess the fever and perform an unscheduled assessment or visit 
as appropriate. Study  staff may  also contact the subject to obtain additional information if a 
temperature of >102
F is entered into an e -diary . Temperature will be measured and 
recorded to 1 decimal place and then groupe d into ranges for the analy sis according to 
Table 3below .
Table 3. Ranges for Fever
100.4F to 101.1F (38.0C to 38.4C)
101.2F to 102.0F (38.5C to 38.9C)
102.1F to 104.0F (39.0C to 40.0C)
>104.0F (>40.0C)

PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 497.2.3.4. Use of Antipyretic/Pain Medication
From Day 1 to Day 14, where Day 1 is the day of vaccination, the subject will be asked to 
record the use of antipyretic and/or pain medication used to treat symptoms (yes/no) in the e-diary in the evening.
7.3. Immunogenicity
Blood samples (approximately 50 mL/visit) for immunogenicity assessments will be 
collected from all subjects prior to vaccination (Visit 1/Day 1), at Visit 2 approximately 1 month after vaccination,  
.  Serum samples should be processed and stored as indicated in the SRM.
The total volume of blood collected from each subject will be approximately 120 mL
(Stage 1 subjects) or 150 mL (Stage 2 subjects) (~50 mL/visit).  Sera will be used for immunogenicity assessments and assay development purposes.
OPA titers for the 7 pneumococcal serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) will be 
determined in all subjects for each blood sample.  Results will be reported as OPA titers.
 
Immunogenicity assays will be performed at Pfizer Vaccine Research & Development 
Laboratory located at 401 North Middletown Road, Pearl River, NY 10965 and/or at a facility designated by Pfizer.
7.4. Laboratory Tests:  Stage 1 Only
The safety laboratory tests will be performed at times defined in the Schedule of Activities
and Section 6 of the protocol.
The FDA toxicity grading scale
61for healthy adult and adolescent volunteers enrolled in 
preventive vaccine clinical trials will be used to grade abnormalities.
If abnormal laboratory parameters are reported at screening and the investigator 
believes the results to be erroneous or to represent stable Grade 1 abnormalities, the abnormal laboratory parameters may be retested. Subjects with stable Grade 1 abnormalities may be considered eligible at the discretion of the investigator.  A “stable” Grade 1 laboratory abnormality is defined as a report of Grade 1 on an initial blood sample that 
remains ≤Grade 1 upon repeat testing on a second sample from the same subject.CCI
CCICCI
PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 50Hem atology Chemistrya
Hem oglobin
Hem atocrit
RBC count
Platelet count
WBC count with differentialBUN/urea and creatinine
AST, ALT
Total bilirubin
Alkaline phosphatase
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea 
nitrogen; RBC = red blood cell; WBC = white blood cell.
a.Please refer to Section 8.4.2 for additional testing required for subjects w ho meet Hy’s law criteria.
7.5. Biological Samples
Blood samples will be used only  for scientific research.  Each sample will be labeled with a 
code so that the laboratory  personnel testing the sa mples will not know the subject’s identity .  
Samples that remain after performing assay s outlined in the protocol may  be stored by  Pfizer. 
Unless a time limitation is required b y local regulations or ethical requirements, the samples 
will be stored for up to 15 y ears after the end of the study  and then destroy ed.  If allowed b y 
the informed consent document, stored samples may  be used for additional testing to better 
understand the immune responses to the vaccine(s) under stud y in this protocol, to inform the 
development of other products, and/or for vaccine- related assay  work supporting vaccine 
programs.  No testing of the subject’s genetic material will be performed.
The subject may request that his or her samples, if still identifiable, be destroy ed at a ny time; 
however, an y data already collected from those samples will still be used for this research. 
The biological samples may be shared with other researchers as long as confidentiality  is 
maintained and no testing of the subject’s genetic material is performed .
8.ADVERSE EVENT REPORT ING
8.1.Requirements
The table below summarizes the requirements for recording safet y events on the CRF and for 
reporting safety  events on the Clinical Trial (CT) SAE Report Form to Pfizer Safet y.  These 
requirements are delineat ed for 3 t ypes of events: (1) SAEs; (2) nonserious AEs; and (3) 
exposure to the investigational product under study  during pregnancy  or breastfeedi ng, and 
occupational exposure.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form  to Pfizer Safety Within 24 
Hours of Awareness
SAE All All
Nonserious AEaAll None
Exposure to the investigational 
product under study during 
pregnancy or breastfeeding, and 
occupational exposureAll (regardless of whether 
associated with an AE), except 
occupational exposureExposure during pregnancy, 
exposure via breastfeeding, 
occupational exposure (regardless 
of whether associated with an AE)
a.Nonserious AEs will be recorded from the time the subject provides informed consent through and 
including Visit 2.  After Visit 2, only NDCMC s (can be nonserious) and SAEs will be reported.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 51All observed or volunteered events regardless of vaccine group or suspected causal 
relationship to the investigational product(s) will be reported as described in the following 
paragraphs.
Events listed in the table above that require reporting to Pfizer Safety  on the CT SAE Report 
Form within 24 hours of awareness of the event by  the investigator are to be reported 
regard less of whether the event is determined by the investigator to be related to an 
investigational product under study .  In particular, if the SAE is fatal or life -threatening, 
notification to Pfizer Safety  must be made immediately , irrespective of the extent of available 
event information.  This time frame also applies to additional new (follow -up) information on 
previously  forwarded reports.  I n the rare situation that the investigator does not become 
immediately  aware of the occurrence of an event, the inve stigator must report the event 
within 24 hours after learning of it and document the time of his/her first awareness of the 
event.
For each event, the investigator must pursue and obtain adequate information both to 
determine the outcome and to assess whet her it meets the criteria for classification as an SAE 
(see the Serious Adverse Events section below).  In addition, the investigator may be 
requested b y Pfizer Safety to obtain specific follow -up information in an expedited fashion.  
This information is m ore detailed than that recorded on the CRF .  In general, this will include 
a description of the event in sufficient detail to allow for a complete medical assessment of 
the case and independent determination of possible causalit y.  An y information relevant to 
the event, such as concomitant medications and illnesses, must be provided.  I n the case of a 
subject death, a summary of available autopsy  findings must be submitted as soon as possible 
to Pfizer Safety .  An y pertinent additional information must be r eported on the CT SAE 
Report Form; additional source documents (eg, medical records, CRF, laboratory  data) are to 
be sent to Pfizer Safet y ONLY upon request.
As part of ongoing safet y reviews conducted b y the sponsor, an y nonserious AE that is 
determined b y the sponsor to be serious will be reported by the sponsor as an SAE.  To assist 
in the determination of case seriousness, further information may  be requested from the 
investigator to provide clarity  and understanding of the event in the context of the c linical 
study .
For Stage 1 subjects, the investigator must contact the Pfizer study  physician directly as soon 
as possible after becoming aware of a nonprompted severe AE or SAE occurring within 
14days after vaccination.  Additional information regarding such events and the reporting 
requirements can be found in the SRM or equivalent.
8.1.1. Additional Details on Recording Adverse Events on the CRF
All events detailed in the table above will be recorded on the AE page(s) of the CRF.  I t 
should be noted that the CT SAE Report Form for reporting of SAE information is not the 
same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the same AE t erm should be used on both the CRF and the CT SAE Report 
Form for reporting of SAE information.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 528.1.2. Eliciting Adverse Event Information
The investigator is to record on the CRF all directly  observed AEs and all AEs spontaneously  
reported b y the stud y subject. In addition, each study  subject will be questioned about the 
occurrence of AEs in a nonleading manner.
8.1.3. Withdrawal From the Study Due to Adverse Events (see also the Subject 
Withdrawal Section)
Withdrawal due to AEs should be distinguished from withdrawal due to other causes, 
according to the definition of AE noted b elow, and recorded on the CRF.
When a subject withdraws from the study  because of an SAE, the SAE must be recorded on 
the CRF and reported, as appropriate, on the CT SAE Report Form, in accordan ce with the 
Requirements section above.
8.1.4. Time Period for Collecting AE/SAE Information
The time period for actively eliciting and collecting AEs, SAEs , and NDCMCs (“active 
collection period”) for each subject begins from the time the subject provides inform ed 
consent, which is obtained before the subject’s participation in the study  (ie, before 
undergoing an y stud y-related procedure and/or receiving investigational product), through 
and including Visit 2 .  
Between Visit 2 and Visit 3 (Stage 1) and Visit 2 an dVisit 4 
(Stage 2), only NDCMCs and SAEs will be reported.  An NDCMC is defined as a disease or 
medical condition, not previously  identified, that is expected to be persistent or is otherwise 
long-lasting in its effects.
For subjects who are screen failur es, the active collection period ends when screen failure 
status is determined.
8.1.4.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a subject during the active collection period are reported to Pfizer 
Safety  on the CT SAE Report Form.
SAEs occurring in a subject after the active collection period has ended are reported to Pfizer 
Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility  of being related to investigational 
product must be reported to Pfizer Safety .
Follow -up by  the investigator continues throughout and after the active collection period and 
until the event or its sequelae resolve or stabilize at a level acceptable to the investigator, and 
Pfizer concurs with that assessment.
8.1.4.2.
Recording Nonserious AEs and SAEs on the CRF
During the active collection period, both nonserious AEs and SAEs are recorded on the CRF.
Follow -up by  the investigator may  be required until the event or its sequelae resolve or 
stabilize at a level acceptable to the investigator, and Pfizer concurs with that assessment.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 538.1.5. Causality Assessment
The investigator’s assessment of causalit y must be provided for all AEs (serious and 
nonserious); the investigator must record the causal relationship on the CRF, and report such 
an assessment in accordance with the SAE reporting requirements, if applicable.  An 
investigator’s causalit y assessment is the determination of whether there exists a reasonable 
possibility  that the investigational product caused o r contributed to an AE; generall y the facts 
(evidence) or arguments to suggest a causal relationship should be provided.  If the 
investigator does not know whether or not the investigational product caused the event, then 
the event will be handled as “related to investigational product” for reporting purposes, as 
defined b y the sponsor.  If the investigator's causality assessment is “unknown but not 
related” to investigational product, this should be clearl y documented on study  records.
In addition, if the investigator determines that an SAE is associated with study procedures, 
the investigator must record this causal relationship in the source documents and CRF, and 
report such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
8.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities
AE reporting, including suspected unexpected serious adverse reactions, will be carried out 
in accordance with applicable local regulations.
8.2.Definitions
8.2.1. Adve rse Events
An AE is an y untoward medical occurrence in a study subject administered a product or 
medical device; the event need not necessaril y have a causal relationship with the treatment 
or usage.  Examples of AEs include, but are not limited to: 
Abnor mal test findings;
Clinically  significant signs and sy mptoms;
Changes in physical examination findings;
Hypersensitivity ;
Progression/worsening of underl ying disease ;
Drug abuse;
Drug dependency .
Additionally , AEs may  include signs and s ymptoms resulting f rom:
Drug overdose;

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 54Drug withdrawal;
Drug misuse; 
Drug interactions;
Extravasation;
Exposure during pregnancy  (EDP);
Exposure via breastfeeding;
Medication error;
Occupational exposure.
8.2.2. Abnormal Test Findings
Abnormal objective test findings should be recorded as AEs when an y of the following 
conditions are met: 
Test result is associated with accompan ying symptoms; and/or
Test result requires additional diagnostic testing or medical/surgical intervention; and/or
Test result leads to a change in study  dosi ng (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional concomitant drug 
treatment, or other therapy; and/or
Test result is considered to be an AE b y the investigator or sponsor.
Merel y repeating an abnormal test, in the absence of any  of the above conditions, does not 
constitute an AE.  An y abnormal test result that is determined to be an error does not require 
recording as an AE.
8.2.3. Serious Adverse Events
An SAE is any  untoward medical occurrence at a ny dose that:
Results in death;
Is life -threatening (immediate risk of death);
Requires inpatient hospitalization or prolongation of existing hospitalization;
Results in persistent or significant disability /incapacity  (substantial disruption of the 
ability to conduct normal life functions);

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 55Results in congenital anomaly /birth defect.
Or that is considered to be:
An important medical event.
Medical and scientific judgment is exercised in determining whether an event is an important 
medical event.  An importa nt medical event may  not be immediately  life-threatening and/or 
result in death or hospitalization.  However, if it is determined that the event may  jeopardize 
the subject or may  require intervention to prevent one of the other AE outcomes, the 
important m edical event should be reported as serious.
Examples of such events are intensive treatment in an emergency  room or at home for 
allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; 
or development of drug dependency  or drug abuse.
Medical device complaints may  meet the SAE reporting requirement criteria (see the Medical 
Device Complaint Reporting Requirements section).  An incident is an y malfunction (ie, the 
failure of a device to meet its performance specifications or to perform as intended; 
performance specifications include all claims made in the labeling for the device) that, 
directly  or indirectl y, might lead to or might have led to the death of a subject, or user, or of 
other persons, or to a serious deteriorati on in th eir state of health.
A serious injury  that can cause a serious deterioration in state of health can include:
Alife-threatening illness, even if temporary  in nature;
Apermanent impairment of a body function or permanent damage to a body structure;
A condition necessitating medical or surgical intervention to prevent the above 2 bulleted 
items;
oExamples: clinically  relevant increase in the duration of a surgical procedure; a 
condition that requires hospitalization or significant prolongation of exi sting 
hospitalization;
Any indirect harm as a consequence of an incorrect diagnostic or in vitro diagnostic 
device test results when used within the manufacturer’s instructions for use;
Fetal distress
, fetal death, or an y congenital abnormality  or birth de fects.
8.2.4. Hospitalization
Hospitalization is defined as any initial admission (even less than 24 hours) in a hospital or 
equivalent healthcare facility , or any  prolongation of an existing admission.  Admission also 
includes transfer within the hospital to an acute/intensive care unit (eg, from the psy chiatric 
wing to a medical floor, medical floor to a coronary  care unit, or neurological floor to a 

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 56tuberculosis unit).  An emergency  room visit does not necessarily constitute a hospitalization; 
however, the event leading to the emergency  room visit is assessed for medical importance.
Hospitalization does not include the following:
Rehabilitation facilities;
Hospice facilities;
Respite care (eg, caregiver relief);
Skilled nursing facilities;
Nursing homes;
Same -day surgeries (as outpatient/same -day/ambulatory  procedures).
Hospitalization or prolongation of hospitalization in the absence of a precipitating clinical 
AE is not in itself an SAE.  Examples include:
Admission for treatment of a preexisting condition not associated with the development 
of a new AE or with a worsening of the preexisting condition (eg, for workup of a 
persistent pretreatment laboratory  abnormality );
Social admission (eg, subject has no place to sleep);
Administrative admission (eg, for yearly physical examination);
Protocol -specified admission during a study  (eg, for a procedure required by  the study  
protocol);
Optional admission not associated with a precipitating clinical AE (eg, for elective 
cosmetic surgery );
Hospitalization for observati on without a medical AE;
Preplanned treatments or surgical procedures.  These should be noted in the baseline 
documentation for the entire protocol and/or for the individual subject .
Diagnostic and therapeutic noninvasive and invasive procedures, such as s urgery , should not 
be reported as SAEs.  However, the medical condition for which the procedure was 
performed should be reported if it meets the definition of an SAE.  For example, an acute 
appendicitis that begins during the reporting period should be rep orted if the SAE 
requirements are met, and the resulting appendectomy  should be recorded as treatment of the 
AE.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 578.3.Severity Assessment
GRADE If required on the AE page of the CRF, the investigator w ill use the adjectives MILD, 
MODERATE, orSEVERE to describ e the maximum intensity of the AE. For purposes of 
consistency, these intensity grades are defined as follows:
1 MILD Does not interfere with subject's usual function.
2 MODERATE Interferes to some extent with subject's usual function.
3 SEVERE Interferes significantly with subject's usual function.
Note the distinction between the severit y and the seriousness of an AE.  A severe event is not 
necessarily  an SAE.  For example, a headache may  be severe (interferes significantly  with 
the subject's usu al function) but would not be classified as serious unless it met one of the 
criteria for SAEs, listed above.
8.4.Special Situations
8.4.1. Protocol -Specified Serious Adverse Events
There are no protocol -specified SAEs in this study.  All SAEs will be reported to Pfi zer 
Safety  by the investigator as described in previous sections, and will be handled as SAEs in 
the safet y database.
8.4.2. Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some subjects, transaminase elevations are a harbinger of a more 
serious potential outcome.  These subjects fail to adapt and therefore a re "susceptible" to 
progressive and serious liver injury , commonly  referred to as drug- induced liver injury  
(DILI).  Subjects who experience a transaminase elevation above 3 times the upper limit of 
normal ( ×ULN) should be monitored more frequently  to det ermine if they are an “adaptor” 
or are “susceptible.”
Liver function tests (LFTs) are not required as a routine safet y monitoring procedure in 
Stage 2 ofthis study .  However, should an investigator deem it necessary  to assess L FTs 
because a subject presen ts with clinical signs/sy mptoms, such L FT results should be 
managed and followed as described below.
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (TBili) elevati ons (>2 ×ULN) by  several 
days or weeks.  The increase in TBili ty picall y occurs while AST/ALT is/are still elevated 
above 3 ×ULN (ie, AST/AL T and TBili values will be elevated within the same lab oratory
sample).  In rare instances, by  the time TBili elev ations are detected, AST/AL T values might 
have decreased.  This occurrence is still regarded as a potential DILI.  Therefore, abnormal 
elevations in either AST OR AL T in addition to TBili that meet the criteria outlined below 
are considered potential DILI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medical events, even before all other possible causes of liver injury 
have been excluded.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 58The threshold of laboratory  abnormalities for a potential DILI case depends on the su bject’s 
individual baseline values and underl ying conditions.  Subjects who present with the 
following laboratory  abnormalities should be evaluated further as potential DILI (Hy ’s law) 
cases to definitivel y determine the etiology of the abnormal laboratory values:
Subjects with AST/AL T and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value >2 ×ULN 
with no evidence of hemoly sis and an alkaline phosphatase value <2 ×ULN or not 
available;
For subjects with baseline AST OR ALT ORTBili values above the ULN, the following 
threshold values are used in the definition mentioned above, as needed, depending on 
which values are above the ULN at baseline:
oPreexisting AST or ALT baseline values above the normal range: AST or ALT values 
>2times the baseline values AND >3 × ULN; or >8 × ULN (whichever is smaller).
oPreexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the val ue reaches >3 × ULN 
(whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case s hould b
e reviewed with the sponsor.
The subject should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results.  This evaluation should 
include laboratory  tests, detailed history , and physical assessment.
In addition to repeating measurements of AST and AL T and TBili, laboratory  tests should 
include albumin, creatine kinase (CK), direct and indirect bilirubin, gamma -glutamyl 
transferase (GGT), prothrombin time (PT)/international normalized ratio (INR), total bile 
acids, alkaline phosphatase ,and acetaminophen drug and/or protein adduct levels.  
Consideration should also be given to drawing a separate tube of clotted blood and an 
anticoagulated tube of blood for further testing, a s needed, for further contemporaneous 
analyses at the time of the recognized initial abnormalities to determine etiology .  A detailed 
history , including relevant information, such as review of ethanol, acetaminophen (either b y 
itself or as a coformulated p roduct in prescription or over -the-counter medications) , 
recreational drug, supplement (herbal) use and consumption, family  history , sexual history , 
travel history , history  of contact with a jaundiced person, surgery , blood transfusion, history  
of liver or allergic disease, and potential occupational exposure to chemicals, should be 
collected.  Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging 
(eg, b iliary  tract) may  be warranted.
All cases demonstrated on repeat testing as m eeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  Such potential DILI (Hy’s law) 

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 59cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been rece ived and have excluded an alternative etiology .
8.4.3. Exposure to the Investigational Product During Pregnancy or Breastfeeding, and 
Occupational Exposure
Exposure to the investigational product under study  during pregnancy  or breastfeeding and 
occupational expo sure are reportable to Pfizer Safety  within 24 hours of investigator 
awareness.
8.4.3.1. Exposure During Pregnancy
For both unapproved/unlicensed products and for marketed products, an EDP occurs if:
A female becomes, or is found to be, pregnant either while receiv ing or having been 
exposed (eg, because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pregnant after discontinuing and/or 
being exposed to the investigational product;
An example of environm ental exposure would be a case involving direct contact 
with a Pfizer product in a pregnant woman (eg, a nurse reports that she is pregnant 
and has been exposed to chemotherapeutic products).
A male has been exposed (eg, because of treatment or environment al exposure) to the 
investigational product prior to or around the time of conception and/or is exposed during 
his partner’s pregnancy .
If a subject or subject’s partner becomes or is found to be pregnant during the subject’s 
treatment with the investigati onal product, the investigator must report this information to 
Pfizer Safety  on the CT SAE Report Form and an EDP supplemental form, regardless of 
whether an SAE has occurred.  In addition, the investigator must submit information 
regarding environmental e xposure to a Pfizer product in a pregnant woman (eg, a subject 
reports that she is pregnant and has been exposed to a cy totoxic product by inhalation or 
spillage) to Pfizer Safety  using the EDP supplemental form.  This must be done irrespective 
of whether an AE has occurred and within 24 hours of awareness of the exposure.  The 
information submitted should include the anticipated date of delivery  (see below for 
information related to termination of pregnancy ).

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 60Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP supp lemental form.  In the case of a live birth, the structural 
integrity  of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integri ty of the terminated fetus should be assessed by  gross visual inspection (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic p regnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.
Additional information about pregnancy  outcomes that are reported to Pfizer Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed abortion;
Neonatal deaths that occur within 1 month of birth should be reported, without regard to 
causality , as SAEs.  In addition, infant deaths after 1 month should be reported as SAEs 
when the investigator assesses the infant death as related or possibly  related to exposure 
to the investigational product.
Additional information regarding the EDP may  be requested by  the sponsor.  Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -
up on 
preterm infants to identify developmental delay s).  In the case of paternal exposure, the 
investigator will provide the subject with the Pregnant Partner Release of Information Form 
to deliver to his partner.  The investigator must document in the source documents that the 
subject was given the Pregnant Partner Release of Information Form to provide to his 
partner.
8.4.3.2. Exposure During Brea stfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to Pfizer Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding repo rt is not created when a Pfizer 
drug specifically  approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is repo rted together with the exposure during breastfeeding.
8.4.3.3. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact with the 
product, which may  or may  not lead to the occurrence of an AE.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 61An occupational exposure is reported to Pfizer Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the inf ormation does not pertain to a subject enrolled in the study , the 
information is not recorded on a CRF; however, a copy  of the completed CT SAE Report 
Form is maintained in the investigator site file.
8.4.4. Medication Errors
Other exposures to the investigationa l product under study  may  occur in clinical trial settings, 
such as medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form  to Pfizer Safety 
Within 24 Hours of Awareness
Medication errors All (regardless of whether 
associate d with an AE)Only if associated with an SAE
Medication errors may  result from the administration or consumption of the investigational 
product b y the wrong subject, or at the wrong time, or at the wrong dosage strength.
Medication errors include :
Medica tion errors involving subject exposure to the investigational product;
Potential medication errors or uses outside of what is foreseen in the protocol that do or 
do not involve the participating subject ;
The administration of expired investigational produc t;
The administration of an incorrect investigational product;
The administration of an incorrect dosage;
The administration of investigational product that has undergone temperature excursion 
from the specified storage range, unless it is determined by  the sponsor that the 
investigational product under question is acceptable for use.
Such medication errors occurring to a stud y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately .
Whether or not the medication error is accompanied by  an AE, as determined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applica ble, an y associated AEs, serious and nonserious, are reco rded on an AE page of the 
CRF.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 62Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE .
8.5. Medical Device Complaint Reporting Requi rements
All medical device complaints, regardless of whether the medical device complaint is 
associated with an AE, will be recorded on the applicable pages within the CRF.  This 
includes potential incidents or malfunctions associated with the use of a med ical device 
product.  An incident or malfunction is an event that might have led to death or serious 
deterioration in health, or if it occurred again might lead to death or serious deterioration in 
health.
Pfizer is to be notified of all medical device com plaints within 24 hours of the investigator’s 
awareness of the event.
9. DATA ANALYSIS/STATIS TICAL METHODS
Detailed methodolog y for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in a s tatistical analysis plan(SAP) , which will be 
maintained by  the sponsor.  The SAP may modify  what is outlined in the protocol where 
appropriate ; however, any  major modifications of the primary  endpoint definition s or their 
analyses will also be reflected in a protocol a mendment.
9.1.Sample Size Determination
The study  size is not based on any formal statistical hy pothesis test. In Stage 1, 
approximatel y 33 adults per vaccine group are planned to be randomized in order to have 
approximatel y 30 evaluable subjects per vaccine group .  In Stage 2, a pproximately  220adults 
per vaccine group are planned to be randomized in order to have approximately  200 
evaluable subjects per vaccine group .  No formal statistical comparisons between vaccine 
groups are planned.
Table 4shows the probability  of observing at least 1AE, local reaction ,or sy stemic event for 
a given true event rate of a particular event, at various sample sizes of each study  stage. For 
example, if the true chance of an event is 5%, the probab ility of observing at least 1 such 
event is 0.816 for a Stage 1 sample size of 30 subjects and 0.999 for a Stage 2 sample size 
of 200 subjects.
Table 4. Probability of Observing at Least 1AE, Local Reaction ,
or Systemic Event 
by A ssumed True Event Rates W
ith Different Sample Sizes
Sample Size Assumed True Event Rate of at Least 1AE, Local Reaction ,or System ic Event
Stage 1 3% 5% 10% 12%
N = 33 0.634 0.816 0.969 0.985
Stage 2 1% 3% 5%
N = 220 0.890 0.999 0.999

PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 639.2. Analysis Populations
In Stage 1, the safety population will include all subjects who receive at least 1 dose of 
c7vPnC or Tdap. In Stage 2 the safety population will include all subjects who receive at least 1 dose of c7vPnC or PPSV23.  Subjects will be assigned to vaccine groupscorresponding to the vaccine actually received within each of the 2 study stages, respectively.  The safety population will be the only analysis population for the primary endpoints for each study stage.
 evaluable immunogenicity populations are defined: the 1-month postvaccination 
evaluable immunogenicity population in each of Stage 1 and Stage 2
. The evaluable 
immunogenicity population for each study stage will generally include any subject
•who does not meet any exclusion criteria and meets all inclusion criteria, 
•who has no major protocol deviations as determined by the clinician, and 
•who receives the assigned vaccine, as randomized.
Furthermore, for the 1-month postvaccination evaluable immunogenicity populations in 
Stage 1 and Stage 2, separately, 
•whose Visit 2 at the 1-month blood draw collection is within 27 to 49 days, inclusive, 
after vaccination, and 
•who has at least 1 valid and determinate assay result for at least 1 serotype for Visit 2 
(1 month after vaccination).
 
 
 
 
The evaluable immunogenicity populations will be the primary analysis populations for 
immunogenicity results.
The all-available immunogenicity population will be defined for each postvaccination blood 
draw collection visit.  Each all-available population will include all subjects who receive vaccine and have at least 1 valid and determinate assay result at the indicated visit. The all-available immunogenicity populations will be the secondary analysis populations for immunogenicity results. Subjects will be assigned to their randomized study vaccination.CCICCI
CCI
CCI
PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 649.3. Immunogenicity Analysis
Secondary endpoints include both GMTs 1 month after vaccination and GMFRs measured 
from before vaccination to 1 month after vaccination.  GMTs and GMFRs will be calculated for each OPA assay within each study stage age group separately.  Ninety-five percentconfidence intervals (CIs) will also be obtained.  Each serotype will be analyzed separately.
 
 
GMTs and their CIs will be obtained by taking log transforms of titers, calculating the 95% 
CI with reference to the t-distribution, then exponentiating the mean and the limits. GMFRs and their CIs will be obtained by first dividing the indicated postbaseline titer (at 1 month  
by the baseline titer and log transforming the ratios.  The GMFR and its CI will 
be calculated using the same method as for GMTs.
 
 
  
 
 
 
 
9.4. Safety Analysis
Descriptive statistics will be compiled for each safety endpoint for each vaccine group within 
each age group, separately. In each of Stage 1 and Stage 2 groups, local reactions and systemic events from Day 1 to Day 14 after study vaccination will be presented by severity and cumulatively across severity levels.  Descriptive statistics will include proportions of subjects with the indicated endpoint and the associated Clopper-Pearson 95% CIs.
AEs (including nonserious AEs, SAEs, and NDCMCs) with causality and severity will be 
summarized from vaccination until Visit 2, approximately 1 month (28-35 days) after vaccination for Stage 1 and Stage 2. Additionally, SAEs and NDCMCs will be presented from vaccination until approximately 6 months after vaccination (both Stage 1 and Stage 2) and 12 months after vaccination (Stage 2 only).  The descriptive statistics for AEs will be summarized as the number and percentage of subjects reporting at least 1 event of each preferred term with the associated Clopper-Pearson 95% CIs, arranged by system organ class, and will also be summarized as the number of occurrences of the event.CCI
CCI
CCIC
CI
CCI
PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 65 
 
9.5. Analysis Timing
During this multistage study, the following analyses will occur:
Stage 1
1. Unblinded descriptive analyses of Stage 1 safety data through the 1-month 
postvaccination visit to permit start of Stage 2.
2. Unblinded immunogenicity data from the 1-month postvaccination visit from Stage 1 will 
be analyzed when it is available.  Analyses will be descriptive.
3. Unblinded descriptive analyses of the 6-month postvaccination safety data will be
conducted when data are available.
Stage 2
1. Unblinded descriptive analyses for the 1-month postvaccination time point for Stage 2 
will be conducted when the safety and immunogenicity data are available. This analysis will inform internal program development decisions and provide safety and immunogenicity data to support end–of–Phase 2 regulatory interactions for development of an adult indication.
2. Unblinded descriptive analyses of the 6-month and 12-month postvaccination safety data 
will be conducted when data are available.
 
There will be no alpha adjustments for these analyses.
Investigator sites and laboratory personnel directly conducting the immunogenicity assays 
will remain blinded until the study database has been locked and unblinded.
 
 
 
 CCICCICCI
PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 66 
 
 
 
 
10. QUALITY CONTROL AND QUALITY ASSURANCE
Pfizer or its agent will conduct periodic monitoring visits during study conduct to ensure that 
the protocol and GCPs are being followed.  The monitors may review source documents to confirm that the data recorded on CRFs are accurate.  The investigator and institution will allow Pfizer monitors/auditors or its agents and appropriate regulatory authorities direct access to source documents to perform this verification.  This verification may also occur after study completion.
During study conduct and/or after study completion, the investigator site may be subject to 
review by the IRB/EC, and/or to quality assurance audits performed by Pfizer, or companies working with or on behalf of Pfizer, and/or to inspection by appropriate regulatory authorities.
The investigator(s) will notify Pfizer or its agents immediately of any regulatory inspection 
notification in relation to the study. Furthermore, the investigator will cooperate with Pfizer or its agents to prepare the investigator site for the inspection and will allow Pfizer or its agent, whenever feasible, to be present during the inspection.  The investigator site and investigator will promptly resolve any discrepancies that are identified between the study data and the subject's medical records.  The investigator will promptly provide copies of the inspection findings to Pfizer or its agent.  Before response submission to the regulatory authorities, the investigator will provide Pfizer or its agents with an opportunity to review and comment on responses to any such findings.
It is important that the investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the process.
11. DATA HANDLING AND RECORD KEEPING
11.1. Case Report Forms/Electronic Data Record
As used in this protocol, the term CRF should be understood to refer to either a paper form or 
an electronic data record or both, depending on the data collection method used in this study.
A CRF is required and should be completed for each included subject.  The completed 
original CRFs are the sole property of Pfizer and should not be made available in any form to third parties, except for authorized representatives of Pfizer or appropriate regulatory authorities, without written permission from Pfizer.CCI
PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 67The investigator has ultimate responsibility  for the collection and reporting of all clinical, 
safet y,and laboratory  data entered on the CRFs and any  other data collection forms (source 
documents) and ensuring th at they  are accurate, authentic /original, attributable, complete, 
consistent, legible, timely  (contemporaneous), enduring ,
and available when required.  The 
CRFs must be signed by  the investigator or by  an authorized staff member to attest that the 
data contain ed on the CRFs are true. Any correcti ons to entries made in the CRFs or source 
documents must be dated, initialed ,and explained (if necessary ) and should not obscure the 
original entry .
In most cases, the source documents are the hospital or the ph ysician subject chart.  In these 
cases ,data collected on the CRFs must match the data in those charts.
In some cases, the CRF may  also serve as the source document.  In these cases, a document 
should be available at the investigator site and at Pfizer that clea rly identifies those data that 
will be recorded on the CRF, and for which the CRF will stand as the source document.
11.2. Record Retention
To enable evaluations and/or inspections/ audits from regulatory  authorities or Pfizer, the 
investigator agrees to keep rec ords, including the identity  of all participating subjects 
(sufficient information to link records, eg,CRFs and hospital records), all original signed 
informed consent documents, copies of all CRFs, safet y reporting forms, source documents, 
and detailed r ecords of treatment disposition, and adequate documentation of relevant 
correspondence ( eg,letters, meeting minutes, and telephone call reports).  The records should 
be retained b y the investigator according to the ICH guidelines
, according to local 
regul ations, or as specified in the c linical study agreement (CSA) , whichever is longer.
If the investigator becomes unable for an y reason to continue to retain study records for the 
required period ( eg, retirement, relocation), Pfizer should be prospectivel y notified.  The 
study  records must be transferred to a designee acceptable to Pfizer , such as another 
investigator, another institution, or an independent third party  arranged by  Pfizer.
Investigator records must be kept for a minimum of 15 y ears after compl etion or 
discontinuation of the study or for longer if required by applicable local regulations.
The investigator must obtain Pfizer's written permission before disposing of an y records, 
even if retention requirements have been met.
12.ETHICS
12.1. Institutional Re view Board/Ethics Committee
It is the responsibility  of the investigator to have prospective approval of the study  protocol, 
protocol amendments, informed consent documents, and other relevant documents, eg,
recruitment advertisements, if applicable, from the IRB/EC.  All correspondence with the
IRB/EC should be retained in the investigator f ile.  Copies of IRB/EC approvals should be 
forwarded to Pfizer.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 68The only  circumstance in which an amendment may  be initiated prior to IRB/EC approval is 
where the chang e is necessary  to eliminate apparent immediate hazards to the subjects.  In 
that event, the investigator must notify  the IRB/EC and Pfizer in writing immediately  after 
the implementation.
12.2. Ethical Conduct of the Study
The study  will be conducted in accordance with the protocol, legal and regulatory  
requirements, and the general principles set forth in the I nternational Ethical Guidelines for 
Biomedical Research Involving Human Subjects (Council for International Organizations of 
Medical Sciences [CIOMS] 2002), ICH Guideline for G ood Clinical Practice , and the 
Declaration of Helsinki .
12.3. Subject Information and Consent
All parties will ensure protection of subject personal data and will not include subject names 
or other identifiable data in any reports, publicat ions, or other disclosures, except where
required b y law.
When study  data are compiled for transfer to Pfizer and other authorized parties, s ubject 
name s, address es, 
and other identifiable data will be replaced b y numerical code sbased on a 
numbering sy stem provided by  Pfizer in order to de -identify  study  
subject s.The investigator
site will maintain a confidential list of subjects who participated in the study ,linking each 
subject’s numerical code to his or her actual identity .  In case of data transfer, Pfizer will 
maintain high standards of confidentialit y and protection of subjects’ personal data consistent 
with applicable privacy  laws .
The informed consent document sand an y subject recruitment materials must be in 
compliance with ICH GCP, local regula tory requirements, and legal requirements
, including 
applicable privacy  laws .
The informed consent document s used during the informed consent process and an y subject 
recruitment materials must be reviewed and approved by  
Pfizer , approved by  the IRB/EC
before use , and available for inspection.
The investigator must ensure that each study  subjec t is fully  informed about the nature and 
objectives of the stud y and possible risks associated with participation.
The investigator, or a person designated b y the inve stigator, will obtain written informed 
consent from each subject before an y study -specific activity  is performe d. The investigator 
will retain the original of each subject's signed consent document .
12.4. Reporting of Safety Issues and S erious B reaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of any  new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, Pfizer s hould be informed immediately .

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 69In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study subjects against an y immedia te hazard, and of 
any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.
13.DEFINITION OF END OF TRIAL
13.1. End of Trial i n the Participating Countr y
End of trial in all participating countries is defined as l ast subject last visit (LSLV).After 
this time, sites will be closed out, the I RB/EC will be informed, and no further CIOMS 
reports will be sent.
14.SPONSOR DISCONTINUAT ION CRITERIA
Premature termination of this study  may  occur because of a regulatory  authority  decision, 
chan ge in opinion of the IRB/EC , orinvestigational product safety  problems, or at the 
discretion of Pfizer.  In addition, Pfizer retains the right to discontinue development of
c7vPnC at any  time.
If a stud y is prematurel y terminated, Pfizer will promptly  notify the investigator.  After 
notification, the investigator must contact all participating subjects and the hospital pharmacy  
(if applicable) within 30 day s.  As directed by  Pfizer, all study  materials must be collected 
and all CRFs completed to the greate st extent possible.
15.PUBLICATION OF STUDY RESULTS
15.1. Communication of Results by Pfizer
Pfizer fulfills its commitment to publicly disclose clinical trial results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the Europe an Clinical Trials 
Database (EudraCT), and/ or www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations.
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the study  or the country  in 
which the study  was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial US Basic Results on www.clinicaltrials.gov for Pfizer- sponsored 
interventional studies (conducted in patients )that evaluate the safet y and/or efficacy of a 
Pfizer product , regardless of the geographical location in which the study is conducted.  US 
Basic Results are submitted for posting within 1 year of the primary  completion date (PCD) 
for studies in adul t populations or within 6 months of the PCD for studies in pediatric 
populations.
PCD is defined as the date that the final subject was examined or received an intervention for 
the purposes of final collection of data for the primary  outcome, whether the c linical study  
concluded according to the pre specified protocol or was terminated.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 70EudraCT
Pfizer posts European Union ( EU)Basic Results on EudraCT for all Pfizer -sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 y ear of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.
www.pfizer.com
Pfizer posts Public Disclosure Sy nopses (clinical study  report sy nopses in which any  data 
that could be used to identify  individual patients have been removed) on www.pfizer.com for 
Pfizer -sponsored interventional studies at the same time the US Basic Results document is 
posted to www.clinicaltrials.gov.
15.2. Publications by Investigators
Pfizer suppor ts the exercise of academic freedom and has no objection to publication by  the 
PI of the results of the s tudy based on information collected or generated by  the PI , whether 
or not the results are favorable to the Pfizer product.  However, to ensure aga instinadvertent 
disclosure of confidential i nformation or unprotected inventions, the i nvestigator will provide 
Pfizer an opportunity  to review an y proposed publication or other t ype of disclosure of the 
results of the study (collectively , “p
ublication”) before it is submitted or otherwise disclosed.
The i nvestigator will provide any publication to Pfizer at least 30 day s before it is submitted 
for publication or otherwise disclosed. If any patent action is required to protect intellectual 
propert y rights, the investigator agrees to delay  the disclosure for a period not to exceed an 
additional 60 day s.
The i nvestigator will, on request, remove an y previously  undisclosed confidential 
information bef ore disclosure, except for any  study-or Pfizer product -
related information 
necessary  to the appropriate scientific presen tation or understanding of the s tudy results.
If the study  is part of a multi centerstudy , the investigator agrees that the first publication is 
to be a joint publication covering all investigator sites, and that an y subsequent publications 
bythe 
PIwill reference that primary  publication . However, if a joint manuscript has not 
been submitted for publication within 12 months of co mpletion or termination of the s tudy at 
all participating sites, theinvestigator is free to publish separatel y, subject to the other 
requirements of this s ection.
For all publications relating to the s tudy, 
the institution will comply  with recognized ethical 
standards concerning publications and authorship, including Sect ion II -“Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, 
established by  the International Committee of Medical Journal Editors.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 71Publication of study  results is also provided for in the CSA between Pfizer and the 
institution.  I n this section entitled Publications by  Investigators, the defined terms shall have 
the meanings given to them in the CSA.
If there is an y confli ct between the CSA and an y attachments to it, the terms of the CSA 
control.  If there is an y conflict between this protocol and the CSA, this protocol will control 
as to any  issue regarding treatment of s tudy subjects, and the CSA will control as to all other 
issues.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 7216.REFERENCES
1Said MA, Johnson HL , Nony ane BA, Deloria -Knoll M, O’Brien KL ; for 
the AGEDD Adult Pneumococcal Burden Study  Team . Estimating the 
burden of pneumococcal pneumonia among adults: a sy stematic review 
and meta -analysis of diagnostic techniques. PLoS One . 
2013;8(4):e60273.
2O'Brien KL, Wolfson L J, Wat t JP, et al. Burden of disease caused b y 
Streptococcus pneumoniae in children younger than 5 years: global 
estimates. Lancet . 2009;374(9693):893-902.
3Huang SS, Johnson KM, Ray  GT, et al. Healthcare utilization and cost of 
pneumococcal disease in the Unit ed States. Vaccine .
2011;29(18):3398 -3412.
4Iyer AS, Ohtola JA, Westerink MAJ . Age -related immune response to 
pneumococcal poly saccharide vaccination: lessons for the clinic. Expert 
Rev Vaccines. 2015;14(1):85 -97.
5Jain S, Self WH, Wunderink RG, et al; 
for the CDC EPI C Study  Team . 
Community -acquired pneumonia requiring hospitalization among US 
adults. N Engl J Med. 2015;373(5):415 -427.
6Jain S, Williams DJ, Arnold SR, et al; for the CDC EPI C Study  Team . 
Community -acquired pneumonia requiring hospitalizat ion among US 
children. N Engl J Med. 2015;372(9):835-845.
7Moore MR , Link-Gelles R, Schaffner W, et al. Effect of use of 13- valent 
pneumococcal conjugate vaccine in children on invasive pneumococcal 
disease in children and adults in the USA: analy sis of m ultisite, 
population -based surveillance. Lancet Infect Dis . 2015;15(3):301-
309.
8Centers for Disease Control and Prevention.  Active Bacterial Core 
Surveillance (ABCs) Report, Emerging Infections Program Network, 
Streptococcus pneumoniae , 2015. http://www .cdc.gov/abcs/reports -
findings/survreports/spneu1 5.pdf. Updated 25 Apr 2016. Accessed 
26Jun2017.
9World Health Organization. 23- valent pneumococcal poly saccharide 
vaccine. WHO position paper. Wkly Epidemiol Rec . 2008;83( 42
):373-
384.
10Geno KA, Gilbert GL, Song JY, et al. Pneumococcal capsules and their 
types: past, present, and future. Clin Microbiol Rev . 2015;28(3):87 1-899.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 7311Hausdorff WP, Hanage WP. I nterim results of an ecological experiment -
conjugate vaccination against the pneumococcus and serot ype 
replacement. Hum Vaccin Immunother. 2016;12(2):358-374.
12Austrian R.A brief history  of pneumococcal vaccines. Drugs Aging.
1999;15 (suppl 1 ):1-10.
13Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy  of 
polyvalent pneumococcal poly sacchari de vaccine. N Engl J Med.
1991;325(21):1453 -1460.
14Stein KE. Thy mus- independent and thy mus- dependent responses to 
polysaccharide antigens. J Infect Dis. 1992;
165(s uppl 1 ):S49-S52 .
15Borrow R, Heath PT, Siegrist CA. Use of pneumococcal poly saccharide 
vacci ne in children: what is the evidence? Curr Opin Infect Dis. 
2012; 25(3):292-303.
16Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration 
of 13 -valent pneumococcal conjugate vaccine and 23
-valent 
pneumococcal poly saccharide vaccine in pneumococcal vaccine -naive 
adults 60- 64 years of age. Vaccine. 2014;32(20):2364 -2374.
17Jackson L A, Gurtman A, van Cleeff M, et al. Influence of initial 
vaccination with 13 -valent pneumococcal conjugate vaccine or 23 -valent 
pneumococcal poly saccharide vaccine on a nti-pneumococcal responses 
following subsequent pneumococcal vaccination in adults 50 y ears and 
older. Vaccine . 2013;31(35):3594-3602.
18Torling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 
23-valent pneumococcal poly saccharide vaccine in middle -aged and 
elderl y persons previously treated for pneumonia. Vaccine . 
2003;22(1):96 -103.
19Jackson L A, Neuzil KM, Yu O, et al ; for the Vaccine Safet y Datalink . 
Effectiveness of pneumococcal polysaccharide vaccine in older adults. 
NEngl J Med
. 2003;348(18):1747-1755.
20Leventer -Roberts M, Feldman BS, Brufman I , Cohen -Stavi CJ, Hoshen 
M, Balicer RD . Effectiveness of 23- valent pneumococcal poly saccharid e 
vaccine against invasive disease and hospital -treated pneumonia among 
people aged  65 years: a retro spective case -control study . Clin Infect Dis.
2015; 60(10):1472-1480.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 7421Torres A, Bonanni P, Hry niewicz W, Moutschen M, Reinert RR, Welte 
T.Pneumococcal vaccination: what have we learnt so far and what can 
we expect in the future? Eur J Clin Microbiol Infe ct Dis . 2015; 34(1):19-
31.
22Black SB, Shinefield HR, L ing S , et al. Effectiveness of heptavalent 
pneumococcal conjugate vaccine in children younger than five years of 
age for prevention of pneumonia. Pediatr Infect Dis J . 
2002;21(9):810 -815.
23Hansen J, Bl ack S, Shinefield H, et al. Effectiveness of heptavalent 
pneumococcal conjugate vaccine in children younger than 5 years of age 
for prevention of pneumonia: updated anal ysis using World Health 
Organization standardized interpretation of chest radiographs . 
Pediatr 
Infect Dis J . 2006;25(9):779-781.
24Kaplan SL, Center KJ, Barson WJ, et al. Multicenter surveillance of 
Streptococcus pneumoniae isolates from middle ear and mastoid cultures 
in the 13- valent pneumococcal conjugate vaccine era. Clin Infect Dis . 
201
5;60(9):1339 -1345.
25Cutts FT, Zaman SM, Enwere G, et al; Gambian P neumococcal Vaccine 
Trial Group. Efficacy  of nine -valent pneumococcal conjugate vaccine 
against pneumonia and invasive pneumococcal disease in The Gambia: 
randomised, double -blind, placebo -controlled trial. Lancet.
2005; 365(9465):1139-11 46.
26Eskola J, Kilpi T, Palmu A, et al ; for the Finnish Otitis Media Study  
Group. Efficacy  of a pneumococcal conjugate vaccine against acute otitis 
media. N Engl J Med. 2001;344(6):403 -409.
27O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safet y of seven -
valent conjugate pneumococcal vaccine in American Indian children: 
group ran domised trial. Lancet. 2003;362(9381):355
-361.
28Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce 
N; for the Vac cine Trialists Group . A trial of a 9 -valent pneumococcal 
conjugate vaccine in children with and those without HIV infection. 
NEngl J Med. 
2003;349(14):1341-1348.
29Whitney  CG, Farley  MM, Hadler J, et al ; for the Active Bacterial Core 
Surveillance of the E merging I nfections Program Network . Decline in 
invasive pneumococcal disease after the introduction of protein-
polysaccharide conjugate vaccine. N Engl J Med. 
2003;348(18) :1737 -1746.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 7530Pilishvili T, Lexau C, Farley MM, et al ; Active Bacterial Core 
Surveill ance/Emerging Infections Program Network. Sustained 
reductions in i nvasive pneumococcal disease in the era of c onjugate 
vaccine .J Infect Dis. 2010; 201(1):32-41.
31Reinert RR, Paradiso P, Fritzell B. Advances in pneumococcal vaccines: 
the 13
-valent pneumoc occal conjugate vaccine received market 
authorization in Europe. Expert Rev Vaccines . 2010;9(3):229 -236.
32Centers for Disease Control and Prevention. Licensure of a 13 -valent 
p
neumococcal conjugate vaccine (PCV13) and recommendations for use 
among childre n --Advisory Committee on Immunizatio n Practices 
(ACI P), 2010.  MMWR Morb Mortal Wkly Rep. 2010; 59(9) :258-261.
33Centers for Disease Control and Prevention. Licensure of 13 -valent 
pneumococcal conjugate vaccine for adults aged 50 y ears and older.  
MMWR Mo rb Mortal Wkly Rep. 2012;61(21):394 -395.
34Prevenar 13 Summary  of Product Characteristics. 
http://www.ema.europa.eu/docs/en_GB/document_library /EPAR_ -
_Product_I nformation/human/001104/WC500057247.pdf. Accessed 
29Jun2017.
35European Medicines Agency . Prev enar 13 Assessment Report. 
22January  2015.  
http://www.ema.europa.eu/docs/en_GB/document_library /EPAR_ -
_Assessment_Report_ -_Variation/human/001104/WC500186805.pdf . 
Accessed 29 Jun2017.
36World Health Organization. WHO 
Prequalified Vaccines. Pneumococcal 
(conjugate). Prevenar 13. https://extranet.who.int/gavi/PQ_Web/Preview 
Vaccine.aspx?nav=0&ID=221. Effective 20 Aug 2010. Accessed 
12 Sep
2016.
37World Health Organization. WHO Prequalified Vaccines. Pneumococcal 
(conjugate). Prevenar 13 Multidose Vial. 
https://extranet.who.int/gavi/PQ_Web/PreviewVaccine.aspx?nav=0&ID=
317. Effective 14 Jul 2016. Accessed 12 Sep 2016.
38Harboe ZB, Dalb y T, Weinberger DM, et al. Impact of 13-v
alent 
pneumococcal conjugate vaccination in invasive p neumococcal disease 
incidence a nd m ortality [erratum appears in Clin Infect Dis
. 
2014;59(12):1812] . Clin Infect Dis. 2014;
59(8): 1066 -1073.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 7639Steens A ,Bergsaker MA, Aaberge IS, Ronnig K, Vestrheim DF . Prompt 
effect of replacing the 7 -valent pneumococcal conjugate vaccine with the 
13-va lent vaccine on the epidemiology  of invasive pneumococcal disease 
in Norway . Vaccine. 2013 ;31(52) :6232-623 8.
40Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness 
of the new serot ypes in the 13-valent pneumococcal conjugate vaccine. 
Vaccine .2011; 29(49):9127-9131.
41Bruce MG, Singleton R, Bulkow L
,et al. Impact of the 13- valent 
pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal
disease and carriage in Alaska. Vaccine. 2015;33( 38):4813-4819 .
42Cohen R, Biscardi S, L evy C. Th e multifaceted impact of pneumococcal 
conjugate vaccine implementation in children in France between 2001 to 
2014. Hum Vaccines Immunother. 2016;12(2):277 -284.
43Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-
valent pne umococcal conjugate vaccine on pneumococcal 
nasophary ngeal carriage in children with acute otitis media. Pediatr 
Infect Dis J. 2012; 31(3):297 -301.
44Flasche S, Van Hoek AJ, Sheasby  E, et al. Effect of pneumococcal 
conjugate vaccination on seroty pe-specific carriage and in
vasive disease 
in England: a cross- sectional study . PLoS Med. 2011 ;8(4):e1001017.
45Williams SR, Mernagh PJ, L ee MH, Tan JT. Changing epidemiology  of 
invasive pneumococcal disease in Australian children after introduction 
of a 7 -valent pneumococcal conjugate vaccine. Med J Aust.
2011; 194(3):116-120.
46Lepoutre A, 
Varon E, Georges S, Gutmann L, Levy -Bruhl D. Impact of 
infant pneumococcal vaccination on invasive pneumococcal diseases in 
France, 2001-2006. Euro Surveill . 2008; 13(35) :18962.
47Munoz -Almagro C, Ciruel a P, Esteva C, et al; for the Catalan Study  
Group of Invasive Pneumococcal D isease .Seroty pes and clones causing 
invasive pneumococcal disease before the use of new conjugate vaccines 
in Catalonia, Spain. J Infect. 2011 ;63(2):151-162.
48Norton NB, Stanek RJ, Mufson MA. Routine pneumococcal vaccination 
of children provokes 
new patterns of s eroty pes causing invasive 
pneumococcal disease in adults and c hildren. Am J Med Sci.
2013;345(2):112-120.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 7749Adam HJ, Karlowsky  JA, Nichol KA, et al. Baseline epidemiology  of 
Streptococcus pneumoniae serot ypes in Canada prior to the introduction 
of the 13-valent pneumococcal vaccine. Microb Drug Resist.
2012; 18(2):176
-182.
50Gonzalez BE, Hulten KG, L amberth L, Kaplan SL, Mason EO Jr;
U.S. 
Pediatric Multicenter Pneumococcal Surveillance Group. Streptococcus 
pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal 
infections in children in the United States after the introduction of the 
pneumococcal 7 -valent conjugate vaccine. Pediatr Infect Dis J.
2006; 25(4):301-305.
51Harboe ZB, 
Thomsen RW, Riis A, et al. Pneumococcal serot ypes and 
mortality  following invasive pneumococcal disease: a population -based 
cohort study . PLoS Med. 2009; 6(5):e1000081.
52Wroe PC, Lee GM, Finkelstein JA, et al. Pneumococcal carriage and 
antibiotic resistance in young children before 13 -valent conjugate 
vaccine. Pediatr Infect Dis J. 2012;31(3):249 -
254.
53Cohen R, Varon E, Doit C, et al. A 13 -year survey of pneumococcal 
nasophary ngeal carriage in children with acute otitis media following 
PCV7 and PCV13 implementation. Vaccine . 2015;33(39):5118-5126.
54Demczuk W HB, Martin I, Griffith A, et al; Toronto Bacterial Diseases 
Network; Canadian Public Health Laboratory  Network . Serot ype 
distribution of invasive Streptococcus pneumoniae in Canada after the 
introduction of the 13 -valent pneumococcal conjugate vaccine, 2010–
2012. Can J Microbiol. 2013;59(12) :778- 788.
55Moore M . Personal communication of ABCs raw data from 2012 to 
2014. 2015.
56Golden AR, Adam HJ, Zhanel GG ;Canadian Antimicrobial Resistance 
Alliance (CARA ). Invasive 
Streptococcus pneumoniae in Canada, 2011 –
2014: characterization of new candidate 15-valent pneumococcal 
conjugate vaccine serot ypes 22F and 33F. Vaccine . 2016;34(23):2527-
2530.
57Duvvuri VR, Deng X, Teatero S, et al. Population structure and drug 
resistance patterns of emerging non -PCV -13 Streptococcus pneumoniae
seroty pes 22F, 15A, and 8 isolated from adults in Ontario, Canada. Infect 
Genet Evol. 2016 Aug 31;42:1
-8.

PF-06842433 ( Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 7858Waight PA, Andrews NJ, L adhani SN, Sheppard CL , Slack MPE, M iller 
E. Effect of the 13- valent pneumococcal conjugate vaccine on invasive 
pneumococcal disease in England and Wales 4 years after its 
introduction: an observational cohort study . Lancet Infect Dis.
2015;15(5):535 -543.
59van der Linden M, Falkenhorst G, P erniciaro S, Imohl M . Effects of 
infant pneumococcal conjugate vaccination on seroty pe distribution in 
invasive pneumococcal disease among children and adults in German y. 
PLoS One. 2015;10(7):e0131494.
60International Conference on Harmonisation. Statistic al Principles for 
Clinical Trials. I CH Harmonised Tripartite Guideline E9, February  1998.
61Food and Drug Administration, C enter for Biologics Evaluation and 
Research. Toxicity  Grading Scale for Healthy  Adult and Adolescent 
Volunteers Enrolled in Preventiv e Vaccine Clinical Trials. Guidance for 
Industry , September 2007.

PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 79Appendix 1. Abbreviations
The following is a list of abbreviations that may be used in the protocol.
Abbreviation Term
7vPnC 7-valent pneumococcal conjugate vaccine
AE adverse event
ALT alanine aminotransferase
AOM acute otitis media
AST aspartate aminotransferase
c7vPnC complementary 7-valent pneumococcal conjugate vaccine
CAP community-acquired pneumonia
CBER Center for Biologics Evaluation and Research
CDC Centers for Disease Control and Prevention
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
COPD chronic obstructive pulmonary disease
CRF case report form
CRM197 cross-reactive material 197
CSA clinical study agreement
CT clinical trial
DILI drug-induced liver injury
DU dispensable unit
EC ethics committee
e-diary electronic diary
EDP exposure during pregnancy
EU European Union
EudraCT European Clinical Trials Database
FDA Food and Drug Administration
FIH first-in-human
FSH follicle-stimulating hormone
GCP Good Clinical Practice
GGT gamma-glutamyl transferase
GMFR geometric mean fold rise
GMT geometric mean titer
HIV human immunodeficiency virus
IB investigator’s brochure
ICH International Council for Harmonisation
ID identification
IND investigational new drug application
INR international normalized ratioCCI
CCI
PF-06842433 (Complementary 7-valent Pneumococcal Conjugate Vaccine)
C3571001
Final Protocol, 28 June 2017
Page 80Abbreviation Term
IPD invasive pneumococcal disease
IRB institutional review board
IRC internal review committee
IRT interactive response technology
IUD intrauterine device
IWR interactive Web-based response
LFT liver function test
LSLV last subject last visit 
N/A not applicable
NDCMC newly diagnosed chronic medical condition
OPA opsonophagocytic activity
PCD primary completion date
PDA personal digital assistant
PI principal investigator
PPSV23 23-valent pneumococcal polysaccharide vaccine
PT prothrombin time
SAE serious adverse event
SAP statistical analysis plan
SRM study reference manual
SRSD single reference safety document
TBD to be determined
TBili total bilirubin
Tdap tetanus, diphtheria, and acellular pertussis vaccine
ULN upper limit of normal
US United States
USPI US package insert
VT vaccine-type
WHO World Health OrganizationCCI
CCI
'RFXPHQW $SSURYDO 5HFRUG
'RFXPHQW 1DPH	

	 
   
 
	
'RFXPHQW 7LWOH  	  !"#$  !%&'%(#  )#( )! &
(*) ) +), )!(%#(#),  #""*!-##), !+ "*()#&() *"!!( !*-) &# # (),  *() 
 )!*-  , !+ -
6LJQHG %\ 'DWH*07 6LJQLQJ &DSDFLW\
	
''
	 	33
 +
 445
	''
	 	63		3 %/
0// (
0 4450PPD
PPD